Nutrient regulation of energy metabolism in relation to obesity and type 2 diabetes by Hvammen, Andreas Wensaas
Nutrient regulation of energy metabolism in relation 
to obesity and type 2 diabetes
Andreas Wensaas Hvammen
August 2009
Dissertation for the degree of Philosophiae Doctor (Ph.D.)
Department of Nutrition
Institute of Basic Medical Sciences
Faculty of Medicine
University of Oslo
Norway
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Andreas Wensaas Hvammen, 2010 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 907 
 
ISBN 978-82-8072-387-1 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS.  
 
Produced in co-operation with Unipub.  
The thesis is produced by Unipub merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
3Table of contents
Acknowledgements __________________________________________________________ 4
1. Abbreviations ____________________________________________________________ 5
2. List of publications ________________________________________________________ 7
3. Abstract _________________________________________________________________ 8
4. Introduction _____________________________________________________________ 9
Possible causes for insulin resistance and type 2 diabetes______________________________________ 9
Metabolic syndrome __________________________________________________________________ 9
Obesity____________________________________________________________________________ 10
Diabetes mellitus type 2 ______________________________________________________________ 10
Insulin resistance ____________________________________________________________________ 12
Insulin-regulated glucose metabolism ____________________________________________________ 12
Skeletal muscle _______________________________________________________________ 13
Skeletal muscle energy metabolism______________________________________________________ 13
Myokines __________________________________________________________________________ 14
Adipose tissue ________________________________________________________________ 14
Regulation of gene expression by nuclear transcription factors________________________ 15
Liver X receptors____________________________________________________________________ 15
Peroxisome proliferator-activated receptors (PPARs)________________________________________ 16
____________________________________________________________________________ 16
 ____________________________________________________________________________ 17
 ____________________________________________________________________________ 18
Fatty acids ___________________________________________________________________ 18
Structure __________________________________________________________________________ 18
Functions __________________________________________________________________________ 19
Long-chain omega-3 polyunsaturated fatty acids ___________________________________________ 19
Eicosapentaenoic acid ________________________________________________________________ 20
Tetradecylthioacetic acid______________________________________________________________ 20
Obesity and IR/T2D ___________________________________________________________ 21
Plasma free fatty acids________________________________________________________________ 21
Ectopic storage of fat in liver and skeletal muscle __________________________________________ 21
Skeletal muscle and dysfunctions in relation to T2D ________________________________________ 21
Metabolic inflexibility of skeletal muscle _________________________________________________ 22
Mitochondrial dysfunction – 	
 ________________________________________ 22
Adipokines_________________________________________________________________________ 23
Adipose tissue inflammation ___________________________________________________________ 23
Insulin resistance – adipocyte hyperplasia better than hypertrophy?_____________________________ 24
5. Aims of the present study __________________________________________________ 25
6. Summary of papers_______________________________________________________ 26
Paper I: ___________________________________________________________________________ 26
Paper II: ___________________________________________________________________________ 27
Paper III: __________________________________________________________________________ 29
Paper IV: __________________________________________________________________________ 30
7. Discussion______________________________________________________________ 33
8. Conclusion _____________________________________________________________ 39
9. References______________________________________________________________ 40
4Acknowledgements
This work would never have got passed the finish line without the invaluable support, 
guidance and strict reminders of my supervisor professor Christian A. Drevon, to whom I am 
deeply grateful. Thank you for five excellent years both professionally and socially at 
occasions. In addition I would like to mention the members of Drevon’s group for all the nice 
scientific debates at our weekly meetings as well in the lab and elsewhere. Fred Haugen, 
Merethe Rokling-Andersen, Robert Caesar, Anne-Randi Enget and all the others have helped 
both technically and scientifically to develop me as a scientist. Together with the rest of my 
former colleagues at the Department of Nutrition they have created an excellent working 
environment for prosperous research.
Furthermore, I would like to express my deepest appreciation to my former supervisor during 
the work with my Master thesis at the School of Pharmacy; Professor Arild C. Rustan, who 
has been a fantastic collaborator and demonstrated tremendous support throughout my period 
as a PhD student. I would also thank my colleagues in “muskel gruppa” at the School of 
Pharmacy including Eili T Kase, Hege Thoresen and Vigdis Aas for all our interesting 
discussions on myotube metabolism.
I would also express gratitude to all my co-authors for their important contributions. 
Especially Michael Gaster, Stefan Hallén and Jørgen Jensen have been particularly helpful 
giving me technical assistance and valuable scientific input.
Moreover, I would acknowledge Lipgene (Integrated Project 6th Framework Programme, 
Food Quality, and Safety; FOOD-CT-2003-505944), Freia Chocolade Fabriks Medical 
Foundation and The Johan Throne Holst Foundation for Nutrition Research for financial
support.
A special thought goes to Trond Methi, Jacob Ngai, Espen Kolberg and Bjørn Winther. What 
would life be without good friends to discuss topics like home beer making and playing 
Settlers. In addition, I would like to quote my good friend, best man and co-founder of the 
0=1-1 hypothesis, Trond: “Hovedpoenget er at alle muligheter som kan oppstå fra null, vil 
oppstå fra null. Uendelig mange muligheter kan oppstå fra null, og alle disse mulighetene vil
oppstå fra null, fordi de er null. Hvorvidt vårt univers utgjør alle disse mulighetene, eller om 
hvert univers er sin egen entitet, kan vi aldri vite. Det eneste vi vet er at de feltene som utgjør 
vår forståelseshorisont er reelle, og at de har sitt opphav fra null.” Methi T, on the subject of 
0=1-1, 2007.
I would also like to thank my family and friends for their encouragement over the past years. 
In particular I would like to thank my beautiful wife Hanne W Hvammen for always being 
there for me during the process of finishing this work. Although frustrating at times you never 
stopped believing in me, and helped me pull through. I love you darling!
Larvik, August 2009
Andreas J Wensaas 
51. Abbreviations
Type 2 diabetes (T2D)
Peroxisome proliferator activated receptors (PPARs)
Liver x receptors (LXRs)
Triacylglycerols (TAGs)
Eicosapentaenoic acid (EPA)
Tetradecylthioacetic acid (TTA)
Acid soluble metabolites (ASM)
White adipose tissues (WATs)
Uncoupling protein 3 (UPC3)
Tumor necrosis factor alpha (T)
Body mass index (BMI)
International Diabetes Federation (IDF)
C-reactive protein (CPR)
Interleukin-6 (IL-6)
Plasminogen activator inhibitor-1 (PAI-1)
World Health Organization (WHO)
Central nervous system (CNS)
Cholecystokinin (CCK)
Peptide YY (PYY)
Glycogen synthase (GS)
Insulin receptor substrate-1 (IRS-1)
Glucose transporter 1 (GLUT1)
Transcription factor 7-like 2 (TCFL2)
Peroxisome proliferator-activated receptor gamma, co activator 1 alpha ()
Fatty acid synthase (FAS)
Glucokinase (GK)
Phosphoenolpyruvate carboxykinase (PEPCK)
protein kinase B (PBK)
AMP-activated protein kinase (AMPK)
Coenzyme A (CoA)
Brown adipose tissue (BAT)
Messenger RNA (mRNA)
Deoxyribonucleic acid (DNA)
Ribonucleic acid (RNA)
Nuclear receptors (NRs)
9-cis retinoic acid re

Direct repeat 4 (DR4)
C- !"  

ATP-binding cassette transporter 1 (ABC1)
Cholesteryl ester transfer protein (CETP)
Sterol regulatory element-binding protein 1c (SREBP1c)
Acetyl-CoA carboxylase (ACC)
Carbohydrate responsive element-binding protein (ChREBP)
Thiazolidinedione (TZD)
fFatty acid (FA)
Saturated FA (SAFA)
Monounsaturated FA (MUFA)
6Polyunsaturated FA (PUFA)
Docosahexaenoic acid (DHA)
Arachidonic (ARA)
Lipoprotein lipase (LPL)
Very low-density lipoprotein (VLDL)
Toll-like receptors (TLRs)
Free fatty acid receptors (FFARs)
C-Jun N-terminal kinase (JNK)
Nuclear factor kappa B (#$)
Carnityl palmitoyltransferase 1 (CPT1)
Acyl-CoA oxidase (AOX)
Pyruvate kinase (liver) (L-PK)
Free fatty acids (FFA)
Phosphoinositide 3-kinases (PI3K)
Protein kinase c – theta (PKC-%)
&#$'( (&))()
Knock-out (KO)
Diacylglycerol acyltransferase 1 (DGAT1)
Adipose triglyceride lipase (ATGL)
Pyruvate dehydrogenase (PDH)
Phosphofrukrokinase (PFK)
Hexokinase (HK)
Tricarboxylic acid cycle (TCA)
Electron transport chain (ETC)
Reactive oxygen species (ROS)
H
 *+ (,+)
Endoplasmatic reticulum (ER)
Scintillation proximity assays (SPA)
Palmitic acid (PA)
Cluster of differentiation 36/Fatty acid transporter (CD36/FAT)
High-density lipoproteins (HDLs)
72. List of publications
Paper I
Kase ET, Wensaas AJ, Aas V, Højlund K, Levin K, Thoresen GH, Beck-Nielsen H, Rustan 
AC, Gaster M. Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X 
receptor pathway. Diabetes. 2005; 54:1108-15.
Paper II
Wensaas AJ, Rustan AC, Just M, Berge RK, Drevon CA, Gaster M. Fatty acid incubation of 
myotubes from humans with type 2 diabetes leads to enhanced release of beta-oxidation 
products because of impaired fatty acid oxidation: effects of tetradecylthioacetic acid and 
eicosapentaenoic acid. Diabetes. 2009; 58:527-35. 
Paper III
Wensaas AJ, Rustan AC, Lövstedt K, Kull B, Wikström S, Drevon CA, Hallén S. Cell-based 
multiwell assays for the detection of substrate accumulation and oxidation. J Lipid Res. 2007; 
48:961-7.
Paper IV
Wensaas AJ, Rustan AC, Rokling-Andersen MH, Caesar R, Jensen J, Kaalhus O, Graff BA, 
Gudbrandsen OA., Berge RK., Drevon CA. Dietary supplementation of tetradecylthioacetic 
acid increases feed intake but reduces body weight gain and adipose depot sizes in rats fed 
high-fat diets. Diabetes Obes Metab. Accepted for publication 2009 May 9.
83. Abstract
The study of how nutrient intake may influence health and disease is an important and fast 
growing field in research. Different fatty acids and other lipids like cholesterol and its 
derivatives are examples of nutrients capable of regulating their own metabolism as well as 
general energy turnover in many organs.  In pharmacology, drugs have been developed to 
combat dyslipidemia, insulin resistance and type 2 diabetes (T2D) that work through nutrient 
mimicking, stimulating a set of fatty acid sensors called peroxisome proliferator activated 
receptors or PPARs. 
In this thesis we have studied how nutrients may interact with human skeletal muscle cells 
(myotubes) from a T2D background to explain certain traits commonly observed in skeletal 
muscle of people with insulin resistance and T2D. We have showed that mimicking elevated 
levels of cholesterol derivatives (oxysterols) by incubating myotubes with a synthetic ligand 
(T0901317) for the nuclear transcription factors liver x receptors (LXRs), enhanced 
accumulation of fatty acids as triacylglycerols (TAGs) in myotubes, and particularly more in 
myotubes of T2D origin. Furthermore, the allover uptake of fatty acids was strongly increased 
after pretreatment with the LXR activator, whereas fatty acid complete oxidation was only 
raised in the control cells, compensating for the increased fatty acid influx. Moreover, 
preincubating myotubes with the n-3 omega fatty acid eicosapentaenoic acid (EPA) likewise 
increased fatty acid accumulation as TAGs more potently in myotubes derived form T2D 
individuals. We also observed that myotubes from obese type 2 diabetics had lower fatty acid
oxidation as compared to myotubes derived from obese individuals without T2D. The sulfur 
modified fatty acid analogue tetradecylthioacetic acid (TTA) augmented mitochondrial 
carbondioxide (CO2) production in myotubes derived from obese persons with or without 
T2D. However, preincubation with TTA did not fully rescue complete fatty acid oxidation in 
T2D myotubes as their level remained below the average of the controls. Preincubation with 
fatty acids per se all increased fatty acid uptake in myotubes with a concomitant increase in 
 !(-oxidation measured as acid soluble metabolites (ASM) released into the medium 
during incubation with a radiolabeled fatty acid tracer. In T2D myotubes this marker of fatty 
!(-oxidation was increased more after stimuli than in myotubes from obese controls. This 
observation suggests that reduced downstream catabolism in T2D myotubes was compensated 
- !"(-oxidation products.
In this thesis we also investigated the effects of feeding TTA, which may activate all PPAR 
subtypes, on rats fed a high fat diet. The results showed a marked reduction in weight gain 
during a 7 week feeding trial, with a slight increase in feed intake during the last 3 weeks 
resulting in markedly reduced energy efficiency. White adipose tissues (WATs), in particular 
the visceral depots, were reduced by 30-40%. The results may be explained by increased 
futile energy consumption c*!- .*.	(-oxidation by the heart and 
liver, and possibly caused by enhanced energy dissipation due to ectopically expressed 
hepatic uncoupling protein 3 (UPC3). Moreover, ucp1 expression was enhanced in the 
visceral WATs, and may suggest a low grade energy uncoupling in these tissues contributing 
to the reduction in weight gain and dietary energy efficiency.
We have finally devoted a part of this work to the development of two methods for measuring 
cell-associated radiolabeled CO2 production and substrates accumulation. We demonstrated  
accumulation as well as subsequent oxidation of 14C-labeled substrates in cultured human 
myotubes, adipocytes, and hepatocytes. Both methods are adaptable for compound screening 
and provide easy-to-use and time-saving methods for in vitro studies of cellular fuel handling.
94. Introduction
Possible causes for insulin resistance and type 2 diabetes
There is a relationship between obesity and risk of developing insulin resistance and T2D, 
although some individuals seem more protected against obesity-driven T2D than others. 
Current research on the etiology of insulin resistance has revealed two pathways that may 
connect obesity with development of T2D. Firstly, insulin resistant subjects may have reduced
capacity for complete mitochondrial fatty acid oxidation in the liver and especially skeletal 
muscle. In obese individuals, in particular those with high levels of plasma lipids, this can 
lead to an unfavorable balance between fatty acid catabolism to CO2 ! 
!*  (-
oxidation products as well as higher intracellular levels of other potentially cytotoxic fatty 
acid intermediates such as acyl-CoAs, diacylglycerols (DAGs) and ceramides causing insulin 
resistance. Secondly, insulin resistance may be caused or exacerbated by high circulating 
levels of different cytokines/adipokines like tumor necrosis factor alpha (/) and resistin 
derived from inflammatory processes in adipose tissue due to macrophage invasion. Ample 
evidences connect local and circulating inflammatory cytokines to development of some form 
of insulin resistance. Such low-grade inflammation can result from damaged adipocytes when 
exceeding their normal storage capacity, either due to increased risk of physical damage to 
their integrity or lack of proper microvascularization leading to hypoxia. Some data indicate 
that adipocyte hyperplasia rather than hypertrophy might increase the storage capacity for 
fatty acids without the association of low-grade inflammation and consequently insulin 
resistance. Whether this holds for human adiposity is uncertain, but a correlation between
adipocyte size and degree of insulin resistance might partly explain why not all obese 
individuals are similarly affected with insulin resistance and T2D. By combining the first and 
second mechanistic approach one may envision that subjects with both reduced capacity for 
mitochondrial fatty acid oxidation and reduced capacity for fatty acid storage by adipocyte 
hyperplasia would be more prone to develop insulin resistance and T2D when becoming 
obese. On the other hand subjects with both high fatty acid oxidative and high storage 
capacity would be better protected against insulin resistance and T2D at high body mass index 
(BMI).
Metabolic syndrome
Overweight, obesity, T2D and insulin resistance are interconnected so strongly that the use of 
the term metabolic syndrome has become very common. Hyperglycemia is often observed 
together with dyslipidemia and hypertension, and these abnormalities appear to be associated 
with central obesity, insulin resistance, inflammation and thrombosis. This clustering of signs
is further associated with increased risk of developing cardiovascular diseases and T2D, with 
huge social and economical burdens. Recently, The International Diabetes Federation (IDF) 
introduced a new clinical definition(1). For a person to be classified with metabolic syndrome 
he or she must display central obesity together with at least two of four additional features 
presented in table 1.
In scientific studies, other metabolic factors should be included like measurement of central 
fat distribution with CT/MRI, insulin resistance (other than raised fasting glucose) or levels of 
plasma leptin, adiponectin, c-reactive protein (CPR), TNF0interleukin-6 (IL-6), plasminogen 
activator inhibitor-1 (PAI-1), etc(1).
The age-adjusted prevalence of the metabolic syndrome among United States (US) adults was 
recently estimated to be ~24%, suggesting that about 47 millions Americans shared this 
phenotype by the year 2000(2).
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Table 1) Criteria for the metabolic syndrome.
Primary - must be included for definition Secondary - 2 of 4 necessary for definition
Central obesity (waist circumference)
12+	3124		0
154	
There are some ethnic differences in risk 
based that may allow for improved cut-
points when specific data become available.
Elevated triglycerides 
16		78§
Reduced HDL cholesterol 
<1.03 mmol/L (M), 
<1.29 mmol/L (F) or §
Elevated blood pressure
194		,. 0
15:		,.!#
Elevated fasting plasma glucose
1:6;		78¤
§Specific treatment for this lipid abnormality. #Treatment of previously diagnosed 
hypertension. ¤Previously diagnosed T2D. Adapted from(1).
Obesity
One major common feature of metabolic syndrome is obesity especially located in the visceral 
depots. The prevalence of obesity has been rising globally during the last century, and 
prevalence of obesity (BMI <94'.7	 2) in the US increased by more than 60 %, from ~ 12 % 
of total population in 1991 to ~ 20 % in 2000(3). Another more recent report, estimated the 
prevalence of obese US adults in 2004 to more than 32 %(4). According to the latest 
projections by the World Health Organization (WHO) approximately 2.3 billon adults will be 
overweight and more than 700 million obese world wide by the year 2015(5).
The cause for this obesity epidemic seems to be related to a combination of increased food 
supply (6; 7) and reduced physical activity(8; 9). The palatability and energy density of the 
modern food products also contribute to overnutrition, and the availability of these products 
makes it difficult to prevent hyper-alimentation(10). Regulation of food intake, energy
expenditure and adiposity is governed by many signal molecules designed to maintain energy 
homeostasis. Circulating concentrations of leptin and insulin increase with energy 
accumulation in adipose tissue and bind to receptors in the central nervous system (CNS) 
reducing the energy intake, whereas gastrointestinal peptides like cholecystokinin (CCK) and 
peptide YY (PYY) are released into the blood during a meal and may reduce food intake(11).
The peptide hormone ghrelin on the other hand may function to stimulate appetite(12). CNS 
may also influence energy expenditure via peripheral nervous sympathetic signaling, and 
recently hypothalamic malonyl-CoA has been implicated in controlling feed intake and 
energy consumption in rodents(13). When it comes to who will become obese, there seems to 
be substantial individual variance, probably reflecting genetic and epigenetic differences, 
either protecting against or exacerbating the drive towards obesity(6; 9). E.g. increased non-
exercise (heat producing) energy consumption in response to overeating may constitute a 
protective mechanism against obesity(14). Reduced physical activity also greatly contributes 
to obesity and several associated metabolic diseases like insulin resistance and T2D(15).
Diabetes mellitus type 2
Paralleling the rise in obesity is the prevalence of T2D (fig 1), and among US adults the 
estimated prevalence of T2D increased from 4.9% in 1990 to 6.5% in 1998(16). Worldwide, 
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the estimated adult population with diabetes mellitus was ~170 million in 2000, and more 
than 370 million adults are projected to be afflicted globally by the year 2030(17). Similar 
trends also seem to apply in Norway, with increasing prevalence of obesity and diabetes(18).
T2D was formerly known as non-insulin dependent diabetes mellitus, and is the predominant 
form of diabetes mellitus, accounting for about 80% of all diabetic cases(19). The etiology of 
T2D is not well understood, and probably includes several different genetic and 
environmental factors working in concert(19). Studies on the Pima Indians in Arizona have 
shown a marked connection between developments of T2D and degree of obesity(20). The 
genetic predisposition of T2D is strong with concordance rates between monozygotic twins 
older than 60 years of 35-58%, as compared to 17-20% for dizygotic twins(19). First degree 
relatives of individuals with T2D have increased risk of developing the disease as well as 
being insulin resistant. Many putative candidate genes have been investigated for disruptive 
mutations and polymorphisms, but only a few, including genes encoding PPAR0glycogen 
synthase (GS), insulin receptor substrate 1 (IRS-1), glucose transporter 1 (GLUT1),
transcription factor 7-like 2 (TCFL2) and peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha () have been identified, but accounting for only moderate increased 
risks of developing T2D(19). T2D typically includes a combination of insulin resistance and 
insufficient insulin secretion by pancreatic beta-cells(19), either feature may dominate, but 
both are usually present when clinically diagnosed(21). Insulin resistance is a strong predictor 
of development of T2D (22) and obesity may cause or aggravate insulin resistance(23; 24).
Fig 1. Prevalence of obesity and T2D in US 1994-2007.
Adapted from CDC’s Division of Diabetes Translation. National Diabetes Surveillance 
System available at http://www.cdc.gov/diabetes/statistics.
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Insulin resistance
Insulin resistant individuals are normally characterized as having normal or slightly elevated 
fasting plasma glucose in the presence of elevated insulin concentrations, and they often 
display prolonged postprandial hyperglycemia(25). Reduced response to insulin (i.e. insulin 
resistance) may affect several organs, but skeletal muscles, liver and adipose tissues seem to 
play the major roles in insulin-induced glucose clearance. In effect, insulin resistance reduces 
insulin-stimulated glucose uptake in skeletal muscle and adipose tissue together with reduced 
insulin-mediated inhibition of hepatic glucose output(26). Hyperglycemia due to insulin 
resistance can be avoided as long as the insulin-producing pancreatic beta cells can 
compensate by releasing more insulin(27). By reasons yet not fully elucidated, this 
compensatory mechanism tends to break down over time, thus moving prediabetic individuals 
into overt diabetes mellitus. 
Insulin-regulated glucose metabolism
In skeletal muscle and adipose tissue, insulin enhances glucose uptake by translocation and 
fusion of intracellular vesicles containing the specific glucose transporter GLUT4(28).
Skeletal muscle may further accumulate the incoming glucose as glycogen or catabolize it 
partly to lactate, or completely to CO2 by mitochondrial oxidation. Adipocytes on the other 
hand do not generate glycogen or oxidize glucose to a significant extent; instead glucose is 
utilized to produce the glycerol backbone of TAGs, or broken down to acetate in 
mitochondria and to be further utilized as substrates for de novo fatty acid synthesis via the 
enzyme fatty acid synthase (FAS) located in the cytosol. Insulin also increases fatty acid 
uptake in skeletal muscle and adipoytes, and inhibits lipolysis of TAG stored in adipose 
depots. In the liver, however, insulin functions differently as the liver cells do not exhibit 
GLUT4-mediated insulin-stimulated glucose uptake. Instead glucose uptake is regulated 
downstream of membrane transport (facilitated by GLUT2) by a liver specific hexokinase 
(also called glucokinase; GK) (29; 30) and GS, the rate limiting step in glycogen 
synthesis(31). Glucose entering the hepatocyte may become incorporated into glycogen, 
oxidized or used as substrate for de novo fatty acid synthesis(31). Another important hepatic 
function is regeneration of glucose from lactate and alanine via gluconeogenesis, regulated by 
insulin via the rate limiting enzyme phosphoenolpyruvate carboxykinase (PEPCK)(32).
Insulin regulates glycogen synthesis positively and gluconeogenesis negatively, thereby 
increasing storage and reducing output of hepatic glucose into the blood stream, 
respectively(31; 33).
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Figure 2. Insulin-regulated glucose metabolism.
Insulin regulated glucose metabolism
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The fate of glucose entering the blood after a meal and responses to insulin. After entering the 
cell, glucose may either be stored as glycogen (mainly in skeletal muscle and liver), 
catabolized partly to lactate by working muscle exceeding its oxidative capacity, converted to 
glycerol to form the backbone of TAG (mainly adipocytes), catabolized completely to CO2 to 
produce energy carriers like ATP and NADP (most organs including brain). In adipose tissue 
glucose may also be oxidized to acetate and be further utilized as substrates for de novo fatty 
acid synthesis via FAS. Glucose transporter 1,2 (GLUT1,2), fatty acid synthase (FAS), fatty 
acid (FA), triacylglycerol (TAG), non-esterified fatty acid (NEFA), very low density 
lipoprotein (VLDL), adenosine triphosphate (ATP).
Skeletal muscle
Skeletal muscle constitutes the largest organ in the body accounting for approximately 40% of 
body weight in normal individuals (34). The share mass of this organ renders its importance 
for energy homeostasis, and even at rest it utilizes approximately 30% of total body energy 
expenditure, whereas during hard physical activity energy expenditure rises several-fold(35).
Lack of muscle activity has been associated with increased risk of developing obesity, T2D 
and cardiovascular diseases(36), and reduced muscle energy turnover is associated with 
development of both obesity (35) and T2D(15).
Skeletal muscle energy metabolism
Glucose and fatty acids are quantitatively the primary energy sources for skeletal muscle, with 
resting muscles consuming more fatty acids during fasting, and more glucose when 
carbohydrate uptake increases postprandially(37). Functionally, skeletal muscle can be 
divided in either slow-twitch (type 1) or fast-twitch (type 2) fibers. Differences in fiber type 
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compositions direct preferences for either glucose or fatty acids as the primary fuel. Type 1 
fibers are better adapted for endurance activity, contain more mitochondria and myoglobin
(which makes them redder) and show a preference for fatty acids as primary fuel. On the 
contrary, type 2 fibers appear whiter, have lower capacity for fatty acid oxidation and 
generate energy more anaerobically via glycolysis during contraction(38; 39). All over, 
skeletal muscles are responsible for more than 80% of insulin-stimulated glucose 
disposal(40), and type 1 fibers are more insulin sensitive than type 2 fibers and have higher 
capacity for insulin-stimulated glucose uptake(41). During physical activity, skeletal muscle 
contractions increase glucose uptake via an insulin-independent pathway. Like insulin, 
contraction enhances translocation and budding of small vesicles, containing the glucose 
transporter (GLUT4), with the skeletal muscle plasma membrane, promoting influx of glucose 
from interstitial fluids and thus plasma. Each stimulus generates a unique signaling cascade 
that probably converges on a junction protein called AS160. When phosphorylated by 
upstream AKT/protein kinase B (PBK) (insulin) or AMP-activated protein kinase (AMPK)
(contraction), AS160’s Rab-GTPase activity is inhibited and conversely more Rab-GTP is 
retained, allowing GLUT4 rich vesicles to fuse with the plasma membrane(42). In skeletal 
muscle fatty acids are taken up and esterified with coenzyme A (CoA) and substantial 
amounts of this seem to undergo a cycle into imTAG before being utilized for oxidation(43).
Alternatively, fatty acyl-CoAs may be re-esterified with glycerol or other lipid intermediates 
to produce mono-, di- and triacylglycerols. TAG is the final product of this chain of anabolic 
processes designed for storage of energy, and this storage occurs in small TAG-containing 
lipid droplets. The fatty acids stored as imTAG may then be released and utilized as fuel by 
mitochondria and peroxisomes. 
Myokines
The discovery of adipose tissue as an important source of peptide hormones (adipokines) like 
leptin, adiponectin and resistin(44), has paved the way for the possibility that skeletal muscle 
may produce and release its own myokines(45). Examples like IL-6, IL-8 and IL-15 have 
demonstrated that at least a limited number of these myokines exist, although the functions of 
these factors need to be further studied(46), e.g. with focus on fiber type differences(47).
Potential, new myokines have been hypothesized(48), and many will probably be 
characterized in the near future that may help explain the connection between skeletal muscle 
activity and disease development.
Adipose tissue
There are two main types of adipose tissue, namely white (WAT) and brown (BAT) that
differ markedly in function and localization. WAT is found in subcutaneous layers and around 
the inner body organs (visceral), whereas BAT is mostly located in the neck area of newborn 
children and rodents, but may also be scattered around in association with subcutaneous and 
visceral WAT. The purpose of BAT is to produce heat through a process called non-shivering 
thermogenesis. BAT contains highly specialized brown adipocytes that have large amounts of 
mitochondria enabling them to oxidize fatty acids to produce energy. This energy is then 
released as heat, as BAT mitochondria express a specific uncoupling protein called UCP1, 
allowing protons to flow “freely” through the inner mitochondrial membrane(49). WAT on 
the other hand functions as thermal and mechanical insulation, an energy reservoir for storage 
of TAG and as an endocrine organ secreting adipokines that are involved in regulation of 
energy balance and immune system among other.
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Regulation of gene expression by nuclear transcription factors
Expression of a gene to its corresponding messenger ribonucleic acid (mRNA) and finally as 
its protein product is a process including several steps that may be subject to regulation. The
cells need to tightly regulate their transcriptional machinery to balance the synthesis and 
degradation of the protein products to maintain a steady state within the concentration 
boundaries appropriate for normal function. Regulation of gene expression takes place at 
several levels, from chromatin blocking of transcriptional access to deoxyribonucleic acid
(DNA) to degradation of protein via proteasomes. One important regulatory step determining 
gene expression is the transcription of genes to their corresponding mRNA. To regulate 
mRNA transcription, the cell is equipped with many receptors that sense chemical and 
molecular changes in the extra- and intracellular milieu. These receptors may transfer their 
signals to downstream transcription regulating factors, or may themselves be transcription 
factors. Nuclear transcription factors may enhance or repress the transcriptional process by 
binding to specific DNA sequences associated with the gene, and thereby helping to stabilize 
or destabilize the DNA binding of RNA polymerase II to the core promoter region containing 
the sequence for initiation of transcription. The nuclear receptors (NRs) constitute a large 
superfamily within the category of nuclear transcription factors, with members including 
vitamin D receptor, thyroid hormone receptor, retinoic acid receptor and steroid receptors(50).
Despite decades of research, the endogenous ligands of many NRs still remain unsettled and 
thus these NRs are collectively called orphan receptors. Besides the NRs, several co-
activators and co-repressors work in concert to regulate the functions of e.g. the LXR and 
PPAR transcription factors. The relative importance of these cofactors is starting to be 
unveiled but the field is still young and much is not settled.
Liver X receptors
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of two direct repeats of the sequence AGGTCA with 4 indifferent nucleotides in between; so 
called direct repeat 4 (DR4) type (51)68	 "
!>0!
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macrophages, skeletal muscle, small intestine and kidney(52)0 = 8(  	
ubiquitously expressed(51). LXRs were previously known as orphan receptors, because no 
known endogenous ligands were identified. Over the years, however, several naturally 
occurring oxysterols (cholesterol metabolites) have been shown to activate the LXRs(53; 54),
and more recently glucose was demonstrated to activate LXRs at physiological 
concentrations(55). The finding that cholesterol derivatives, but not cholesterol itself, could 
act as a ligand for LXRs prompted the search for LXR target genes in cholesterol metabolism, 
and the rate limiting enzyme in conversion of ch  - !0  -
 !"   
0 =     .  - !!(56). Later, several genes 
involved in cholesterol, lipid and glucose metabolism have been identified as LXR targets, 
including ATP-binding cassette transporter 1 (ABC1) (57) and cholesteryl ester transfer 
protein (CETP) (58) regulating reverse cholesterol transport, FAS (59) controlling fatty acid 
synthesis, and GLUT4 (60) regulating glucose transport in skeletal muscle and adipocytes. 
LXRs have been extensively studied in regulation of cholesterol homeostasis, stimulating 
reverse cholesterol efflux from peripheral tissues as well as hepatic cholesterol excretion(61),
but less is known about their impact on skeletal muscle fatty acid and glucose metabolism. 
LXRs may positively regulate the mRNA levels and activity of another transcription factor 
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called sterol regulatory element-binding protein 1c (SREBP1c)(62), which is involved in 
promoting insulin-stimulated fatty synthesis via up-regulation of acetyl-CoA carboxylase 
(ACC) and FAS(63). Insulin may increase the levels of hepatic LXRs, and insulin-stimulated 
fatty acid synthesis is dependent on functional LXREs in the promoter region of the SREBP1c 
gene(64). LXRs can also up-regulate the expression of carbohydrate responsive element-
binding protein (ChREBP)(65), which is a transcription factor that is believed to be indirectly 
sensitive to glucose via the metabolite xylose-5-phosphate generated by the pentose 
shunt(66). ChREBP may increase the transcription of genes involved in glucose-derived fatty 
acid synthesis(67). Thus, activating LXRs may directly or indirectly enhance de novo fatty 
acid synthesis as demonstrated by feeding the synthetic LXR-agonist T0901317 to rodents, 
leading to hepatic steatosis and hypertriglyceridemia(68). Furthermore, Kalaany et al. 
demonstrated that LXR-null mice were protected against hypertriglyceridemia and insulin 
resistance induced by high-fat/high-cholesterol feeding through a cholesterol-dependent 
pathway, implicating that LXRs take part in the complex regulation between storage and 
oxidation of fatty acids in hepatic and peripheral tissues(69). However, activation of LXRs 
may produce beneficial effects besides reduction of cholesterol synthesis, as demonstrated by 
improved glucose tolerance in a rodent model of insulin resistance, where addition of the 
LXR-activator GW3965 reduced hepatic gluconeogenesis and improved hepatic glucose 
utilization, and increased glucose uptake in adipose tissue(70). The finding that GLUT4 
"
 *! - .*! -  8  !
 (60; 70), together with a possible 
functional role in skeletal muscle, increasing reverse cholesterol efflux(71), has called for 
further investigations into LXRs functional roles in skeletal muscle.
Peroxisome proliferator-activated receptors (PPARs)
The PPARs are ligand-activated nuclear transcription factors that can be divided into three 
!	00!7(68'80 !	@=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specific response elements (PPREs of DR1 type) in the promoter regions of their target genes. 
The PPARs serve critical roles by “sensing” the presence of fatty acids and eiosanoids, thus 
reciprocally regulating lipid metabolism(72).

The first characterized member of the PPARs was the alpha subtype, which was cloned from 
liver of mice and described as the factor responsible for the peroxisome proliferation induced 
by various carcinogenous xenobiotics(73)6  = * *!  - 
!	 
expressed in liver, but also resides in the heart and skeletal muscle where it influences fatty 
acid oxidation(74)6/
 .>	-*>!- 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development of knock-out animals, showing profound reductions in expression of several 
genes involved in fatty acid oxidation(75)63>0		!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!(-oxidation and ketone body 
production(76; 77). Synthetic ligands ha>-!>
!>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fibrate class frequently used in human medicine as lipid lowering drugs(78). The search for 
endogenous ligands have demonstrated that several long-chain fatty acids may activate 
  		 (79; 80). However, other more specific ligands with 
binding properties in the nanomolar range have been sought that may fit better with the 
concentrations presumed to exist inside the cells. E.g. the high-affinity lipoxygenase 
metabolite 8(S)-HETE has been prop!!.*>(80-82), but its 
subcellular concentrations in relevant tissues have been found to be too low. Thus, it has been 
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an single components(80; 
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83). Alternatively oleylethanolamide, a naturally occurring fatty acid derivative, was recently 
= -
 >>=
 . (84).
Administration of fibrates promotes lowering of serum triacylglycerols, presumably due to 
reduced VLDL-formation due to increased fatty acid oxidation and reduced expression and 
subsequently lower serum levels of apoC-III(85), an inhibitor of VLDL clearance(86).
*	0>=!.!!=
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.
weight gain (87) and insulin resistance induced by feeding high-fat diets(88), but apparently 
this may be at least partly explained by a parallel reduction in feed intake(84; 89).
Surprisingly, selective overexp    ' 	* = ! =
reduced insulin-stimulated glucose uptake and glucose intolerance despite increased fatty acid 
oxidation and protection against diet-induced obesity. 3>0  ''-out (KO)
animals became excessively obese, but remained more glucose tolerant on a high-fat diet than 
wild type animals(90).

/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is the master regulator of adipocyte generation and function(91).  Forced expression of 
-adipogenic cells converts them into mature adipocytes(92), and in knock-out 
mice, although lethal, newborn pups exhibit no adipose tissue development(93)6	 
be activated by endogenous fatty acids (in particular polyunsaturated) (82; 83) or 
eicosanoids(94)6 &. 	
	. >=0>=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glitazone class of drugs, leads to improved insulin sensitivity (95) as well as reduced plasma 
lipids in animals and humans(96)6*	0!	.>	* 
gene in humans are associated with insulin resistance, diabetes mellitus and hypertension(97).
The leading hypothesis underlying these effects are that increased adipose tissue expansion 
and consequently storage of TAG remove plasma lipids, thus relieving liver and skeletal 
muscle from fatty acid-mediated insulin resistance(98-100). Furthermore, activation of 
  
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levels of the prodiabetogenic resistin and TNF are reduced(98). Conditional knock-out of 
PPAR  	* !
  *!  
  ! *  =
progressively reduced amounts of fat stored in adipose tissue. As long as some fat remained, 
however, whole body glucose tolerance and skeletal muscle insulin sensitivity were
unchanged(101). However, in another Cre/Lox mediated adipose tissue specific knock-down 
0>*=	
>!.-fat diet due to enhanced hepatic 
glucose metabolism(102). Although PPAR  
!	  "
!  !
 *0
conditional hepatic knock-down resulted in hyperlipidemia, hyperglycemia and 
hyperinsulinemia besides increased fat storage in adipose tissue, all probably reflecting 
reduced hepatic TAG removal(103)6  	  .*  "
  8B/? !
glucokinase in liver and pancreas, thus affecting hepatic glucose uptake and pancreatic 
glucose-stimulated insulin release(104). Intriguingly, despite very low expression, knocking 
!=   ' 	* *!  
*! * 0 = = -
respondent towards thiazolidinedione (TZD) treatment(105). Hence, the insulin-sensitizing 
and other effects of TZD administration seem to depend at least partly on direct activation of 
   . *0 * ..   
  !
 -mediated plasma 
lipid removal and adipokine regulation causing the beneficial effects of TZD treatment. 
Despite the beneficial effects of TZD on insulin resistance, one major negative side effect is 
weight gain (106) due to a combination of enhanced nutrient intake (107) and increased 
energy efficiency(89; 100; 108; 109). Thus, several drug companies are currently searching 
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for combined or partial agonists for the different PPARs that may prove to have a more 
favorable functional profile than the pure agonists(110).

The third member of the PPAR family, the delta subtype, has traditionally been less studied 
than the other partly because of lack of specific activators like the fibrates and the glitazones. 
  *-C**  "
! = >  . "
  ' 	*(111).
Like the two other PPAR members its endogenous ligands are believed to be fatty acids or 
their derivative eicosanoids(80; 81; 83)6/ *  * -.
unraveled, and recent studies suggest that it might play a major role in energy turnover and 
obesity .*6 D.  6 !!    	
 .*  . 
consumption, by increasing fatty acid combustion and energy uncoupling in tissues when ove-
expressing the receptor or when activating it with a selective ligand. Mice lacking PPA
the other hand showed less adaptive uncoupling response when challenged with a high-fat 
diet, and were more prone to obesity(112)6 E> *! > 	
!  
regulation of fatty acid oxidation in skeletal muscle(113-115). Recently, over-expressing a
*> > variant in skeletal muscle was shown to elicit effects similar to 
those seen during endurance training, with conversion of type 2 to type 1 fibers(116). In 
another recent study, addition of the delta-specific ligand GW1516 to exercising mice further 
increased their exercise-induced generation of fatigue-resistant type 2 fibers and 
synergistically improved their running endurance(117).
Fatty acids
Structure
Fatty acids consist of straight hydrocarbon chains of varying length with a carboxyl acid 
group in one end and a methyl group in the other, where the carbon atoms may be numbered 
(C1, C2, C3,…) from the methyl end. In general, naturally occurring fatty acids have a paired 
number of carbon atoms in their backbone, and they can further be subdivided by the number 
and position of double bounds (unsaturation) in their acyl chain. Fatty acids with no, one or 
more double bounds are termed saturated (SAFA), monounsaturated (MUFA) or 
polyunsaturated (PUFA), respectively. Based on the number of carbon atoms, double bounds 
as well as the position of the first double bound, a systematic nomenclature has been 
constructed. E.g. palmitic acid, a SAFA of 16 carbons, is described as (16:0); oleic acid, a 
MUFA with 18 carbons and one double bound between carbons 9-10, is written (18:1, n-9); 
and the PUFA linoleic acid, with an extra double bound between carbons 6-7 as compared to 
oleic acid, is (18:2, n-6). Ruminant animals contain mostly SAFA and some MUFA, plants 
have more MUFA and PUFA of 16-18 carbons, whereas marine animals may contain 
substantial amounts of long-chain PUFAs (20-22 carbons), because of their food chain is 
based on EPA- (20:5, n-3) and docosahexaenoic acid (DHA)- (22:6, n-3) producing 
algae(118). Mammals may synthesize fatty acids from acetate precursors, but can only 
produce SAFA, MUFA or PUFA of the n-9 type. Thus, because n-6 and n-3 PUFAs have 
essential functions(119), these fatty acids must be obtained via the diet as linoleic (18:2, n-6) 
!-linolenic (18:3, n-3) acids or other fatty acids of the n-6 and n-3 fatty acid families. The 
C18 fatty acids of the n-6 and n-3 fatty acid families can be further elongated and desaturated 
to arachidonic (ARA, 20:4, n-6) and EPA/DHA, respectively(120).
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Functions
Fatty acids serve several important biological functions including energy source, 
phospholipids building blocks in cell membranes, thermal and mechanical insulation (when 
stored as TAG in adipose tissues), as substrates for eicosanoid synthesis (e.g. ARA and EPA), 
protein acylation and ligands for nuclear receptor-regulated gene transcription. Dietary fatty 
acids are absorbed from the gut and re-esterified into TAG in the enterocytes producing 
chylomicrons that enter the blood via lymph drainage. The TAG in chylomicron particles are 
hydrolyzed by lipoprotein lipase (LPL) in the capillaries and the released fatty acids are taken 
up by skeletal muscle, adipose tissue and liver. The liver may utilize fatty acids to produce 
TAG-rich very low-density lipoprotein particles (VLDL) for redistribution of fatty acids to 
peripheral organs. Adipocytes take up fatty acids and glycerol and synthesize TAG for long 
term storage in intracellular lipid droplets, whereas skeletal muscle preferentially utilize fatty 
acids as fuel, but may also store minor amounts as TAG. The liver may also utilize fatty acids 
released from adipocytes during starvation to produce ketone bodies as an alternate fuel 
source to glucose and fatty acids. 
Fatty acids and their ketone body derivatives constitute a major fuel source, particularly after 
24 h fasting, when an estimated ~80% of body energy consumption is provided by lipid 
catabolism(121). Despite their nutritional and essential functions, evidences are pointing 
towards increased fatty acid consumption as an important player in development of obesity, 
insulin resistance and T2D. General lipid overload may result in these negative effects, but 
fatty acid composition likely modulated the responses(122). Diets high in saturated fat are 
associated with increased risk of developing insulin resistance and T2D(123), whereas diets 
rich in monounsaturated fat, like the Mediterranean diet, may prove less prone to such 
detrimental effects(124).
Different types of fatty acids and derivatives may regulate gene transcription by activating or 
inhibiting nuclear transcription factors, but they may also activate receptors in the cell 
membrane like toll-like receptors (TLRs) and free fatty acid receptors (FFARs). In skeletal 
myotubes, activation of TLR2 was shown to be important for palmitic acid-mediated insulin 
resistance by activating an inflammatory signal cascade involving c-Jun N-terminal kinase
(JNK) and nuclear factor kappa B (#$) activity(125). The FFAR, GPR40, is a G-protein 
coupled receptor that can be activated by medium to long-chain fatty acids and thereby induce 
insulin secretion by pancreatic beta cells(126). Fatty acids are also involved in more direct 
regulation of enzyme activity by allosteric activations or repressions, e.g. fatty acyl-CoA 
inhibition of malonyl-CoAs repression of carnityl palmitoyltransferase 1 (CPT1) activity, thus 

	. !(-oxidation(127). Several proteins and peptide hormones are acylated on 
specific amino acid residues, which is important for their proper function. E.g. the gastric 
peptide ghrelin that may regulate appetite, is acylated on a serine residue essential for activity, 
and the acyl moieties used are reflected by the available dietary fatty acids(128).
Long-chain omega-3 polyunsaturated fatty acids
Long-chain n-3 PUFAs like EPA and DHA are one of the best-studied types of fatty acids. 
Marine oils (e.g. cod liver oil) are rich in these n-3 fatty acids, and supplementation with fish 
oils have been associated with reduced insulin resistance and glucose intolerance in animals 
fed high-fat or high-sucrose diets(129-133), although these beneficial effects are not always 
observed in animals fed high-fat diets(124; 134-136). A meta-analysis comparing the effects 
of fish oil on humans with T2D found no improvements in plasma glucose or HbAc1 levels, 
but confirmed the effect of fish oils in lowering plasma triacylglycerols(137). The effect of n-
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3 fatty acids on plasma TAG is probably caused by inhibition of hepatic TAG synthesis and 
VLDL release(138), that most likely is related to reduced hepatic fatty acid synthesis and
increased fatty acid oxidation(139). Studies have demonstrated that feeding long-chain n-3
PUFA may activate hepatic (140) that leads to enhanced expression of genes involved 
   ! (-oxidation like CPT1 and acyl-CoA oxidase (AOX) (141). The reduced 
expression of ACC, FAS and pyruvate kinase (liver) (L-PK) involved in fatty acid synthesis 
may be attributed to negative influence by long-chain n-3 PUFAs on SREBP-1c and 
ChREBP; transcription factors controlling the expression of these genes. PUFAs have been 
shown to negatively affect SREBP-1c mRNA levels(142), possibly via inhibition of 
LXRs(143), and PUFAs may also inhibit the maturating cleavage, and thus activation of 
SREBP-1c(144). Furthermore, PUFAs were shown to negatively influence ChREBP activity 
by reduced mRNA expression and reduced nuclear translocation(145). In PPAR knock-out 
mice the effects of PUFAs on fatty acid oxidation were abolished, whereas the inhibition of 
fatty acid synthesis was not(140; 146).
Fish-oils also may also reduce size of retroperitoneal and epididymal fat depots in rats fed 
high fat diets(147), and these effects are likely due to reduced adipocyte size and not 
number(148). As shown recently, the reduced perirenal and epididymal depots seem to 
involve a redistribution of fat rather than a net reduction, as both total lipid amount and body 
weight remained similar for rats fed high-fat diets with or without fish-oils(149).
Eicosapentaenoic acid
The exact physiological role of EPA in the body or specific organs is less studied as compared 
to fish-oils where EPA is one major constituent. The plasma lipid reducing properties of 
marine n-3 PUFAs may be explained by the presence of EPA, as incubation of cultured rat 
hepatocytes with this fatty acid reduces cholesterol (150) and TAG (151) esterification as well 
as increases palmitoyl-CoA oxidation(152), which in turn reduces synthesis and secretion of 
VLDL (152; 153). In primary human adipocytes preincubation with EPA induced the 
"
   (154) which is important for adipocyte differentiation(100). PP
activation may promote fat accumulation in subcutaneous depots, with reduced or unchanged 
visceral storage(155), that may explain the effects of fish-oils on possible fat tissue 
redistribution mentioned previously. Preincubation of human skeletal myotubes with EPA 
also induced mRNA expression of PPAR and increased both glucose and fatty acid 
uptake(156).
Tetradecylthioacetic acid
The sulfur-substituted fatty acid analogue TTA is a saturated fatty acid containing 16 carbon 
atoms and a sulfur atom inserted between the second and the third carbon counting from the 
carboxyl acid end, making //     ! (-oxidation(157). TTA may reduce 
pla	 
!0 
--  -  . 
	! (-oxidation of fatty acids(158; 
159). TTA reduced epididymal fat in young obese Zucker (fa-fa) rats, as well as epididymal 
and retroperitoneal fat in male Wistar rats fed high-fat diets (70% energy) for three 
weeks(160).
TTA is a pan-PPAR-activator in both rodents and humans(80; 161-164), and dual and pan-
PPAR-agonists are currently being developed for treatment of T2D(110), and TTA has been 
shown to improve glucose metabolism in insulin resistant rats(160) as well as stimulate 
mitochondrial proliferation in rat skeletal muscle(165). We have recently demonstrated that 
TTA may increase   ! "!  *		 *- 	    

agonist GW501516(159).
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Obesity and IR/T2D
Development of insulin resistance, and consequently T2D, may have several distinct but 
related causes that are more or less prominent in each afflicted subject. The obese phenotype 
with raised plasma lipids may cause or aggravate insulin resistance and T2D through different 
mechanisms. 
Plasma free fatty acids
Insulin resistance and T2D are associated with elevated plasma free fatty acids (FFA) levels
(166; 167), and experimental lowering of plasma FFA improved insulin sensitivity in obese 
diabetic and non-diabetic individuals(168). The relevance of fatty acid overload in the 
etiology of T2D is a central feature of lipid-induced insulin resistance, where increased levels 
of intracellular lipid intermediates like acyl-CoAs, DAGs and ceramides interfere with 
intracellular insulin signaling. During experimental infusions of FFA, skeletal muscles of 
healthy individuals become insulin resistant(169; 170), most likely mediated by fatty acid 
interference with INS-1 related activation of phosphoinositide 3-kinases (PI3K), thereby 
inhibiting insulin-stimulated glucose uptake(171-173). Acute high plasma lipid concentrations 
may negatively affect insulin sensitivity through elevation of intracellular acyl-CoA and DAG 
(173) activating protein kinase c – theta (PKC-%) (172) and &#$'( (&))() (174). Mice 
with PKC-% 
 )F were protected against fat-induced skeletal muscle insulin 
resistance(175), showing the importance of this serine kinase in linking high lipid intake with 
disruption of the insulin signaling cascade. Alternatively, increased palmitic acid availability 
may cause insulin resistance through enhanced production of intracellular ceramides 
interfering with insulin signaling possibly by activation of stress-induced serine 
phosphorylation of IRS-1(176).
Ectopic storage of fat in liver and skeletal muscle
A common consequence of obesity is ectopic storage of TAG in tissues other than adipose 
tissue, like liver and skeletal muscle. Intramyocellular TAG (imTAG) storage in untrained 
individuals is a strong predictor of insulin resistance and development of T2D(177-179).
Ectopic storage of TAG in lipid droplets, however, may not by itself be harmful for the cell 
functions, as endurance-trained athletes often have high imTAG levels but at the same time 
show superior insulin-sensitivity compared to sedentary individuals(180; 181). The 
combination of higher capacity for mitochondrial fatty acid oxidation as well as increased 
short term storage of excess TAG, may reduce intracellular lipid intermediates that interfere 
negatively with insulin signaling, thereby relieving insulin resistance(182-185). In fact, 
increased sequestering of incoming fat into imTAG have been shown to decrease lipid 
intermediates and improve insulin sensitivity in transgenic animals either ove-expressing
diacylglycerol acyltransferase 1 (DGAT1) in skeletal muscle(186), or lacking the lipolytic 
enzyme adipose triglyceride lipase (ATGL)(187).
Skeletal muscle and dysfunctions in relation to T2D
The underlying mechanisms explaining skeletal muscle insulin resistance is not settled, and 
may involve more than one process. Different lipotoxic mechanisms have been suggested 
where increased levels of e.g. fatty acyl-CoAs, ceramide, DAG or acylcarnitines negatively 
influence insulin signaling via activation of different serine kinases(26). The mechanisms 
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behind the increased levels of lipid intermediates probably involves the high lipid availability 
observed in the obese state, but other factors likely influence the intracellular lipid milieu in a 
way that promote insulin resistance.
Metabolic inflexibility of skeletal muscle
One central feature observed in many insulin resistant individuals is a lack of flexibility of 
switching from carbohydrate to fatty acid metabolism in skeletal muscles during a fasting
condition, and likewise to increase skeletal muscle utilization of glucose in a response to 
insulin(188; 189). The Randle cycle envisions that increased fatty acid oxidation in skeletal 
muscle may inhibit glucose utilization through feedback inhibition of key enzymes such as 
pyruvate dehydrogenase (PDH) and phosphofrukrokinase (PFK) leading to increased levels of 
glucose-6 phosphate and further inhibition of hexokinase (HK) (190). Likewise, it has been 
suggested an inverse Randle cycle where increased glucose influx generates malonyl-CoA at
a level that inhibits CPT1, and thus reduce fatty acid influx into mitochondria. In the presence
of high plasma TAG and free fatty acid levels such inhibition of fatty acid catabolism might 
generate enough lipid intermediates and byproducts to interfere with insulin signaling(191).
Mitochondrial dysfunction – 	

Several lines of evidence point at mitochondrial dysfunction as important in development of 
skeletal muscle insulin resistance. Reduced mitochondrial number and/or function have been 
observed in studies of skeletal muscle in elderly (192) obese insulin resistant (193) and T2D 
subjects (193; 194) as well as in first degree insulin resistant relatives of people with 
T2D(195; 196). Skeletal muscle mitochondrial oxidative capacity was also found to be a 
better predictor of insulin sensitivity than imTAG or long-chain acyl-CoAs(197). Reduced 
skeletal muscle capacity for fatty acid oxidation may result in harmful levels of lipid 
intermediates(198), and has been associated with increased imTAG levels(192; 195). Reduced 
complete mitochondrial oxidation of fatty acid to CO2 	 
	.>(-
oxidation intermediates interfering negatively with insulin signaling.(199-201).
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twitch type 1 oxidative fibers(202), and its activity seems to control complete mitochondrial 
fatty acids oxidation by regulating the expression of several key enzymes in the tricarboxylic 
acid cycle(TCA) and electron transport chain (ETC) (203). Fatty acid infusion in humans was 
associated with reduced expression of PGC1 and other genes involved in mitochondrial 
metabolism(204). Several studies have observed a correlation between insulin resistance/T2D 
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alone or coordinated with APMK activation, seems necessary for optimal stimulation of 
complete fatty acid oxidation (117).
&!*(-oxidation capacity without concomitant increase in complete oxidation via the 
electron transport chain, may lead to skeletal muscle insulin resistance(200). This was also 
demonstrated by muscle-
  >"
0 .   ! (-oxidation, 
but at the same time reducing insulin sensitivity(90). Koves et al. have proposed that high 
levels of plasma lipids o->! . = - 0 	  !* ' 	* (-
oxidation of fatty acids by activation of PPARs, but without a coordinated down-stream 
!*  -dependent complete oxidation via mitochondrial Krebs cycle and 
electron transport chain/ATP synthase machinery(200). This imbalance between 
	!(-oxidation and complete oxidation may lead to increased mitochondrial stress 
with enhanced production of reactive oxygen species (ROS) and release of excess acyl-
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carnitines, causing insulin resistance(203). Also inherent dysfunctions in complete oxidation 
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and be potentially worsened by obesity and high-fat intake.
D -associated mitochondrial dysfunction can explain all acquired and inherent 
forms of skeletal muscle insulin resistance is presently unknown, but may be unlikely because 
of all the evidence connecting different adipokines and inflammatory cytokines with insulin 
resistance in muscle. In a recent review it was proclaimed that “Skeletal muscle 
‘‘mitochondrial deficiency’’ does not mediate insulin resistance”, enlisting several arguments 
against the concept of mitochondrial dysfunction being the culprit of insulin resistance(207).
Moreover, a study with mice fed a high-sucrose and -fat diet, glucose intolerance and insulin 
resistance preceded the development of mitochondrial damage, mediated by augmented ROS 
production(208). These latter examples display the complexity of understanding the basis of 
insulin resistance, but they do not entirely exclude the compelling possibility of inherent 
mitochondrial defects working in concert to increase the likelihood of developing skeletal 
muscle insulin resistance when the energy balance tips in favor of obesity, thus the issue it not 
yet settled.
Adipokines
Adipose tissues release potent hormone signals called adipokines that may promote insulin 
resistance in obese individuals. Leptin is an adipokine that regulates body weight by reducing 
nutrient intake and increasing energy expenditure, and adipocyte mRNA abundance as well as 
plasma levels of leptin are increased with obesity, providing a feed-back signal from the fat 
stores to the CNS via hypothalamus(209). Disruption of leptin function leads to severe 
hyperphagy, obesity and insulin resistance(210), whereas infusion of leptin may reverse 
insulin resistance and hepatic TAG accumulation in ob/ob and lipodystrophic mice(211). The 
adipokine adiponectin was demonstrated to improve insulin resistance associated with obesity 
and lipoatrophy(212). Disrupting adiponectin resulted in severe diet-induced insulin 
resistance(213), and adipocyte expression of adiponectin was furthermore found to be reduced 
with obesity(214), along with reduced plasma levels(215). Later adiponectin was shown to 
improve insulin resistance by activation of skeletal muscle and hepatic AMPK, stimulating 
fatty acid oxidation and glucose uptake in muscle and reducing gluconeogenesis in liver(216).
Another adipokine, resistin, was identified as an insulin resistance-promoting adipokine, with 
circulating plasma levels positively correlated with adipose tissue size(217). Expression of the 
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may promote insulin resistance(218)6 & 	!  - 0 '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insulin sensitivity(219). In humans, obesity was associated with increased mRNA levels of 
/   * = 
>  != 	*  ulin resistance, and 
=. !* !*! *   =  / !
 * .
expression(220).
Adipose tissue inflammation
Obesity may promote inflammatory processes in adipose tissue and other organs like liver, 
skeletal muscle and pancreas and thus be involved in development of insulin resistance and
T2D(26). During obesity, adipose tissue may expand either by proliferation of new adipocytes 
(hyperplasy) or enlargement of old ones (hypertrophy), although the total number seems to 
change little during adulthood(221). Adipocyte enlargement correlates well with degree of 
insulin resistance (222) and predicts development of T2D better than obesity itself(223).
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When adipocytes enlarge above a certain size they tend to generate inflammation that may be 
linked to microhypoxia (224) and endoplasmatic reticulum (ER) stress(225). Inflamed adipose 
tissue may further release chemokines and attract macrophages that remove damaged cells 
and other debris, forming crown-like structures around necrotic adipocytes(226). Obesity and 
insulin resistance are associated with increased macrophage invasion and inflammation of 
adipose tissue in rodents as well as humans(227; 228). The proinflammatory signaling 
pathways mediated by activation of JNK1(229) and IKK/NF-#$(230) seem to play important 
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of obesity-related insulin resistance (231; 232). Furthermore, conditional knock-downs of 
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fat diet-induced insulin resistance without affecting obesity(229; 230).
Insulin resistance – adipocyte hyperplasia better than hypertrophy?
In transgenic ob/ob mice moderately over-expressing adiponectin Kim et al. (55) observed 
that although the mice grew morbidly obese they were protected against obesity-induced 
insulin resistance, possibly because of adipose tissue hyperplasia rather than 
hypertrophy(233). Tissue inflammation and macrophage invasion were also markedly 
reduced, suggesting that these processes are not merely functions of adipose tissue expansion, 
but possibly related adipocyte size(233). This notion is further supported by the fact that 
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promotes weight gain and enlarged fat tissues, with a reduction in adipocyte size(98; 100; 
234). PPAR >  !* 
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tissue(235), and increases plasma concentration of adiponectin(98).
Ectopic fat storage seems to be dictated by dietary fatty acid availability and storage capacity 
of TAG in adipose tissues, as well as fatty acid uptake and catabolism in target tissues. E.g. 
lipodystrophy is a condition with reduced or abolished adipose tissue fat mass. Consequently, 
reduced fat storage capacity is associated with severe insulin resistance probably due to 
massive ectopic fat storage and increased fatty acid metabolism in skeletal muscle and 
liver(236). Strategies of increasing fatty acid storage capacity of adipose tissues may reduce 
plasma lipids and ectopic TAG storage, thus improving insulin resistance(98; 233).
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5. Aims of the present study
The aims were to: 
1. Study changes in nutrient metabolism of myotubes derived from individuals with type 
2 diabetes (T2D).
2. Study the role of LXR and interaction with specific fatty acids such as EPA and TTA 
in regulating these changes. 
3. Develop more high-throughput and low-cost methodology for assessing cellular 
uptake and CO2-production from radiolabeled energy substrates. 
4. study the impact of feeding TTA to rats on a high-fat background diet, to investigate 
changes in feed intake, body weight gain and sizes of five different adipose tissue 
depots 
The thesis includes four papers:
1) /*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
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regulation of cholesterol metabolism, fatty acid biosynthesis and glucose metabolism. 
In paper I data are presented on the metabolic effects of chronic preincubation with a
LXR activator (T0901317) in human myotubes derived from T2D subjects and lean 
controls. We evaluated whether activation of LXRs induced differential metabolic 
responses in the two types of skeletal muscle cells.
2) Myotubes from individuals with T2D display several differences in glucose and fatty 
acid metabolism. In paper II we investigated whether fatty acids like EPA and TTA 
may influence energy metabolism of cultured myotubes, and if these substances may 
ameliorate the reduced fatty acid oxidation previously observed in myotubes derived 
from obese T2D as compared to cells from obese non-diabetic subjects. 
3) The lack of efficient low-cost methods for screening cellular uptake and CO2-
formation from nutrients such as fatty acids and glucose, prompted us to develop two 
such “fuel handling” systems. Paper III describes the basic principles behind our 
approaches for quantitative measurements of nutrient uptake by scintillation 
proximity assays (SPA) and oxidation to CO2 in cells grown in 96-well standard 
tissue-culture plates.
4) Dual- and pan-PPAR ligands are currently being developed as potential drugs for 
treatment of T2D with associated coronary heart diseases, and TTA has been shown 
to possess pan-PPAR-activation in several studies. However, activators of PPA
	  !*=. . ! ! '  !0 =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may enhance feed intake and increase body weight. In Paper IV we investigated the 
effects of TTA on body weight gain and feed intake in rats fed a lard-based high-fat 
diet, focusing on depot-specific changes in adipose tissue sizes and gene expression 
as well as metabolic changes in plasma, liver, heart and skeletal muscle.
26
6. Summary of papers
Paper I: Skeletal muscle lipid accumulation in type 2 diabetes may involve the 
liver X receptor pathway
This article explores the possible metabolic roles of LXRs in skeletal muscle established from 
obese T2D and lean non-diabetic control subjects. Previous work had shown that activation of 
LXRs constitutes an important regulatory pathway for controlling hepatic cholesterol 
synthesis and lipogenesis. However, some recent studies had also shown that LXR activation 
promoted up-regulation of the muscle and adipocyte specific glucose transporter gene, 
GLUT4. Thus, we conducted this study to investigate the impact of chronic pretreatment with 
the LXR activator T0901317, on glucose and fatty acid intermediary metabolism in myotubes 
from individuals with or without T2D.
We observed enhanced cellular palmitic acid (PA) accumulation, especially as non-esterified 
PA, DAG and TAG. Interestingly, T2D myotubes responded more to LXR-activation as 
compared to control cells, resulting in increased accumulation of DAG and TAG. Some 
myotubes were co-incubated acutely with insulin during PA uptake, which resulted in further 
enhancement of uptake and accumulation of in particular TAG. The effect of LXR-
stimulation was additive to the effect of insulin increasing TAG accumulation by 3-fold as 
compared to non-	*! 6 (-oxidation of PA, measured as ASM, was slightly 
increased by LXR-activation in T2D cells, whereas complete oxidation to CO2 only increased 
in control cells. The stronger increase in cellular PA accumulation, but relatively unchanged 
PA oxidation in T2D myotubes relative to control cells, indicated that LXR-activation 
enhanced partitioning of PA to TAG and other lipids profoundly more in T2D cells. We 
investigated the expression several genes related to lipid metabolism and foun! 80
SREBP-0 0 cluster of differentiation 36/Fatty acid transporter (CD36/FAT), CPT1 
and UCP2 to be up-regulated in myotubes from both donor groups after pretreatment with 
T0901317. There were no significant differences in gene expression between groups, although 
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myotubes after chronic LXR-activation. We observed a dose-responsive increase in insulin-
stimulated glucose uptake after preincubation of myotubes with increasing concentrations of 
T0901317. Similarly, glucose oxidation was enhanced in myotubes after preincubation with 
the LXR agonist. T2D myotubes did not display any significant differences in glucose uptake 
or oxidation as compared to control cells, and thus showed similar responses to LXR-
stimulation. Abundance of GLUT1 and GLUT4 mRNA was increased by LXR activation in 
the myotubes, probably explaining the enhanced insulin-stimulated glucose uptake. However, 
despite a 5-fold increase in GLUT4 mRNA abundance, we observed only about 40% increase 
in insulin-stimulated glucose uptake when pooling the results from both groups, suggesting 
that other mechanisms besides GLUT4 gene expression is important for insulin-regulated 
glucose transport, like intracellular distribution of the transporter.
Skeletal muscles from T2D individuals often display reduced fatty acid oxidation with 
increased deposition of imTAG. An imbalance in uptake and oxidation of fatty acids may 
promote insulin resistance by accumulation of lipotoxic intermediated such as acyl-CoAs, 
DAG and ceramides. We demonstrate a possible role of LXR-activation in accumulation of 
imTAG in skeletal muscle from subjects with T2D. The finding that incubation with 
T0901317 increased DAG as well as TAG in T2D myotubes, may suggest adverse effects of 
activating LXRs on skeletal muscle insulin sensitivity. It is possible that enhanced deposition 
of fatty acids as imTAG may constitute a protective mechanism against high levels of free 
fatty acids known to promote insulin resistance through increased level of intracellular fatty 
acid intermediates. The fact that incubation of myotubes with T0901317 enhanced GLUT4 
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mRNA abundance and promoted enhanced insulin-stimulated glucose uptake, suggests that 
LXR-activation may even prove beneficial in T2D cells.
Paper II: Fatty acid incubation of myotubes from humans with Type 2 Diabetes 
leads to enhanced release of beta oxidation products due to impaired fatty acid 
oxidation: effects of tetradecylthioacetic acid and eicosapentaenoic acid
Different types of fatty acids may have different metabolic effects on skeletal muscle e.g. 
saturated vs. mono- and polyunsaturated fatty acids, where the saturated fatty acids may be 
more diabetogenic than the other types. EPA has been associated with improved skeletal 
muscle insulin response, despite a tendency to enhanced imTAG synthesis and intermediary 
lipid? storage. Skeletal muscle from individuals diagnosed with T2D frequently shows 
reduced mitochondrial fatty acid oxidation and increased imTAG deposition possibly related 
to the development of insulin resistance. TTA is a sulfur-modified fatty acid analogue with 
possible beneficial effects on skeletal muscle fatty acid oxidation and insulin sensitivity. 
Previously, Gaster et al.(237) have demonstrated that myotubes derived from obese T2D 
subjects have reduced capacity for complete oxidation of palmitic acid (PA) to CO2 as
compared to obese control cells, and we have shown that activation of LXRs may promote 
imTAG synthesis specifically in myotubes from individuals with T2D (Paper I). Thus, this 
study was performed to monitor the effects of chronically preincubating myotubes from obese 
T2D and control subjects with EPA and TTA, both bound to fatty acid-free bovine serum 
albumin (BSA). As controls we used both BSA (fatty acid-free control) and oleic acid (OA, 
fatty acid control) at the same molar concentrations as for EPA and TTA.
Our main findings were that T2D myotubes from obese subjects showed reduced complete 
oxidation of 14C-PA to CO2 as compared to myotubes from obese controls. Preincubations 
with fatty acids, in particular EPA, enhanced PA uptake, and both EPA and especially TTA 
!(-oxidation of PA measured as ASM. TTA also improved complete oxidation of PA 
to CO2 in both groups. Thus, after preincubation with TTA, the capacity for compete PA 
oxidation in T2D myotubes was enhanced comparable to the basal level of control myotubes, 
but still remained lower as compared to TTA-preincubated controls. T2D cells displayed 
reduced partitioning of PA into complete mitochondrial CO2 oxidation relative to ASM, and 
when incubated with EPA, TTA or insulin they released significantly more ASM to the media 
than control myotubes. This suggested an impairment of fatty acid oxidation downstream of 
(-oxidation in myotubes from obese T2D as compared to cells from obese non-diabetic 
controls. We further looked at the abundance of important genes involved in fatty acid uptake 
A9;0$90>E8090(-oxidation (CPT1, CPT2, ACADM, HADHB) and 
complete oxidation (CS, MDH2, UCP2, UCP3). There were no differences between the two 
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oxidation (not CPT2 and ACADM) showed increased abundance when myotubes were 
incubated with fatty acids. On the other hand, genes involved in mitochondrial 
oxidation/function were basically unchanged by the preincubations, except for a slight 
(~40%) increase in UCP2 abundance after preincubation with TTA. Preincubation with TTA 
also increased the mRNA abundance of CD36, FABP3 and ACSL3 significantly more than 
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expression induced by fatty acids (mainly EPA and TTA) were reduced in T2D as compared 
to control myotubes, and the changes in these two genes seemed to be positively correlated. 
Besides the enhanced PA oxidation, the enhanced PA uptake promoted by the fatty acid 
preincubations resulted in accumulation of PA in complex lipids, especially TAG. Both 
preincubations with OA and in particular EPA profoundly enhanced PA-derived TAG 
accumulation in the myotubes, whereas preincubation with TTA caused significantly less 
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TAG synthesis than the other fatty acids. The intracellular presence of TTA or TTA-CoA, 
seemed to inhibit DGAT activity as demonstrated by a 7-fold increase in DAG/TAG ratio 
from14C-acetate without change in de novo fatty acid synthesis. Co-incubation with TTA 
during the last 24 h of OA preincubation repressed the OA-induced increase in cell-associated 
PA down to baseline (fatty acid-free BSA control). The relative response in TAG synthesis 
after preincubation with EPA was stronger in T2D cells as compared to obese controls, and 
was reflected in a negative correlation between EPA-induced change in fatty acid oxidation 
and change in TAG formation. However, such correlation was not observed after 
preincubation with OA or TTA. Furthermore, preincubation of myotubes with EPA reduced 
total acyl-CoA, by a marked reduction in C16:0-CoA, C18:1-CoA and C18:2-CoA. Both total 
and C18:2-CoA was significantly more reduced in T2D as compared to obese control 
myotubes, whereas C16:1-CoA was markedly enhanced by preincubation with EPA in both 
groups of cells. Total acyl-CoA was enhanced after preincubation with TTA, but TTA-CoA 
probably accounted for the change. However, in T2D myotubes C18:2-CoA and C20:4-CoA 
both were reduced after TTA-preincubation relative to baseline and obese control myotubes, 
respectively. The cellular metabolism of glucose was basically unchanged after preincubation 
with fatty acids, except for glucose oxidation which was increased by ~ 20% after 
preincubation with EPA as well as TTA. Both T2D and control myotubes exhibited a similar 
increase in glucose oxidation, although allover glucose oxidation was about 10% reduced in 
the diabetic myotubes, further strengthening the notion of a down-stream mitochondrial 
dysfunction. Glucose uptake or glycogen synthesis (basal and insulin-stimulated) were, 
however, not significantly different between the two groups. This may be related to the use of 
control myotubes from obese instead of lean non-diabetic subjects, as used in previous 
studies. Furthermore, the reduced fatty acid oxidation previously observed by Gaster et 
al.(237) was obtained by comparing obese T2D with obese control myotubes, as in this paper.
We observed that myotubes from obese T2D, as compared to obese control individuals, have 
reduced capacity for mitochondrial oxidation, by some unknown mechanism probably down-
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! (-oxidation. Preincubation with fatty acids stimulate the enzymatic 
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to a lesser extent mitochondrial complete oxidation generating CO2. Thus, T2D myotubes 
"-"(-oxidation activity when challenged by fatty acid preincubations, resulting in 
!(-oxidation intermediates. The reduced capacity for removal of fatty acid 
intermediates via complete fatty acid catabolism, may result in increased levels of potentially 
lipotoxic intermediates like acyl-CoAs, DAGs and ceramides, known to negatively affect 
insulin sensitivity and insulin-stimulated glucose disposal. Temporal storage of excess 
incoming fatty acids in imTAG may provide protection against acyl-CoAs and DAGs that are 
substrates for the final enzymatic step in TAG synthesis. In this study we observed that 
preincubation with EPA enhanced TAG synthesis and reduced acyl-CoAs specifically in T2D 
myotubes, besides increasing both glucose and PA oxidation. Thus, EPA may prove 
beneficial for skeletal muscle energy handling in diabetic individuals. Likewise, preincubation 
with TTA enhanced glucose and fatty acid oxidation, and thereby “restored” the complete 
fatty acid mitochondrial oxidation in T2D-myotubes to the baseline level of the obese control 
cells. Preincubation with TTA also opposed the fatty acid-induced increase in TAG synthesis, 
but whether this is a positive effect is unknown as total acyl-CoA level was elevated in cells 
exposed to TTA. However, TTA-CoA probably accounted for this elevation, which may not 
be negative, because we observed that glucose metabolism (basal and insulin-stimulated) was 
unchanged or increased (oxidation) in myotubes preincubated with TTA. Altogether, our data 
from cell experiments suggest that both TTA and EPA may improve overall oxidative glucose 
and fatty acid metabolism in skeletal muscle from T2D as well as obese subjects.
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Paper III: Cell based multiwell assays for detection of substrate accumulation 
and oxidation
Studies investigating cellular metabolism have one feature in common, the difficulty in 
reliably determining substrate oxidation and accumulation in the least time- and resource-
demanding way. Traditionally, substrate oxidation to CO2 has been carried out in small flasks 
(12 cm2) by capturing 14C-labeled CO2 on a filter soaked with an alkali solution while 
maintaining a closed environment to avoid leakage and loss of CO2. This method is far from 
optimal when it comes to amount of “hands-on” time as well as consumption of resources like 
cells, media, substrates, scintillation cocktails and other chemicals. It may therefore be safe to 
say that studies involving measurements of cellular substrate oxidation in relation to 
compound effects or functional disorders have been seriously hampered by the lack of an 
efficient and low-cost method for assessment of CO2 release. Similarly, in many 
circumstances determining how cellular uptake of particular substrates changes with time and 
concentration may be of great importance. These types of measurements are labor intensive, 
time-consuming and usually require a large amount of cells. Thus, there are considerable 
potentials also for improving these types of studies by real-time measuring cellular 
accumulation of radiolabeled substrates with so-called scintillation proximity assays. SPAs 
=(-emitting substrates to be quantitatively determined depending on their accumulation 
in adherent cells growing on the surface of scintillating plastic. Cytostar-TTM, developed by 
Amersham, provide a commercially available system for growing cells in 96-well tissue-
coated plates, and allowing quantitative detection of radiolabeled substrates accumulated 
time-dependently in cells in real time. The main benefit is the ability to measure time-
dependent accumulation of various substrates in the same cells without harvesting the cells. 
Although different products have been on the marked for many years, we could not find any 
description of SPA utilized for the study of cellular accumulation of fatty acids and glucose.
In this work we have developed two general principles for quantitative measurements of 
substrate accumulation and oxidation (to CO2) in living cells growing in a multi-well system. 
Our first approach was to show that 14C-labeled CO2 could be efficiently and reliably captured 
in a 96-well system by applying one standard 96-well tissue-culture plate and one 96-well 
glass fiber filter plate, where each well was sealed with a cover slip. The filters were soaked 
with an appropriate volume of NaOH (1M), and then inverted to be aligned upon the 
corresponding wells of the culture plate. To ensure an air-tight system, a ready made silicon 
gasket with 96 holes was placed between the two plates, each hole aligned with both the 
bottom and top well. Furthermore, the “sandwich” was placed in a custom made 
clamp/apparatus designed to fit snuggly with the bottom 96-well plate, and a precisely cut flat 
metal plate was placed on top of the upper filter plate. The system was finally closed tight by 
applying static pressure on the upper metal plate, delivered by locking a knee-joint handle on 
the clamp in the upright position. To allow quantitative determination of 14CO2 generated 
from living cells, we had to use a bicarbonate-free buffer during incubation. Thus, PBS with 
addition of Ca2+, Mg2+ and HEPES was chosen as standard incubation medium. The 
incubation times tested varied from 2-6 hours, where 4 h was used most frequently. At 
termination of incubation the filter plate was removed, and added a scintillation cocktail and 
counted in 96-= (-counter. With this improved method we could demonstrate a long 
linearity range, comparable results to the previous flask method mentioned above and precise 
measurements of known kinetic parameters, generated from both myotubes and HepG2 cells. 
Our second approach was to investigate the possibility and conditions required for measuring 
time-dependent cell-accumulation of radiolabeled substrates such as fatty acids and glucose in 
human myotubes and SGBS adipocytes by utilizing the SPA technique. Our results 
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demonstrated that the SPA approach produced reliable time-dependent results on 
accumulation of different fatty acid substrates at various concentrations, as well as on insulin-
stimulated glucose uptake.
We use the two methods for quantitative and accurate measurements of accumulation as well 
as oxidation of radiolabeled fatty acids and glucose in myotubes, adipocytes and liver cells. 
Our systems are versatile and can be adjusted to encompass different cell types and types of 
labeled fuels/substrates. One of the main advances is the use of standard 96-well format, 
which allows scintillation counting in commercial 96-well plate readers found in many 
laboratories. All equipments are relatively inexpensive, and the design of the plate-clamp 
should be easy to replicate in a metal workshop, thus making these methods available for 
most scientists. In this article we describe some basic requirements for our methods to work 
satisfactory, although careful optimization is required before applying the same principles to 
other cell types or other substrates.
Paper IV: Dietary supplementation of tetradecylthioacetic acid increases feed 
intake, but reduces body weight gain and adipose depot sizes in rats fed high-fat 
diets
Energy balance in complex organisms such as mammals is obtained by an intricate network of 
hormones, neuropeptides and sympathetic/parasympathetic innervations, controlling energy 
intake via emotions like hunger and satiety as well as regulating energy expenditure by 
physical activity or futile energy cycling (e.g. uncoupling). To avoid development of obesity 
or anorexia, our bodies need to assess the energy density of our diets and balance the energy 
intake with the expenditure. Carbohydrate, protein and fat contain different amount of 
extractable energy, with e.g. palmitic acid per molecule containing more than three times the 
chemical energy compared to a glucose molecule. Thus, fatty acids may signal their presence 
to the body, and one proposed receptor group are the orphan nuclear receptors PPAR alpha, 
delta and gamma. Activation of PPARs may have many different effects depending on the 
organs expressing them, the co-factors associated with their activation and which receptor 
isoform that gets activated. Feeding rats with agonists specific for one isoform is one way of 
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ligand fenofibrate reduce weight and feed intake compared to animals fed a control diet, 
w
 .!.litazon enhances feed intake, body weight gain and 
adipocyte proliferation. Both ligands, however, reduce plasma lipids, but fenofibrate in 
addition enhances HDL-cholesterol and appears cardio protective, whereas rosiglitazon 
improves skeletal muscle insulin sensitivity. In an attempt to take advantage of both the cardio 
protective and insulin sensitizing properties and avoid the adverse effects like weight gain, 
dual- and pan-PPAR activators have been synthesized. 
One such dual PPAR7 > is ragaglitazar promoting reduced plasma lipids but only 
moderate effects on weight change and feed intake in rats. TTA is a synthetic fatty acid 
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!(-oxidation. Several studies have demonstrated that 
TTA is a fairly potent activator of all PPAR-isoforms, where the isoform-specific potency 
may depend partly on cell types and species investigated(158). Besides its beneficial effect on 
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 (-oxidation, enhances mitochondrial and peroxisomal 
proliferation in several tissues, and may reduce visceral fat pads and enhance glucose 
tolerance in high-fat fed rats (238). TTA has also shown promising effects on several cancer 
models(164; 239) and may affect keratinocyte proliferation and differentiation in diseases 
such as psoriasis(163). Although being a pan-PPAR-activator, TTA may execute some of its 
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effects via non PPAR-mediated mechanisms like enzymatic competitive inhibition. Whether 
TTA may affect body weight gain and feed intake in rats fed a high-fat diet similar to other 
PPAR-activators is currently unknown. Thus, this study was performed to investigate the 
long-term impact of adding TTA to a lard-enriched diet providing ~ 40% energy from fat to 
rats up to 7 weeks. The main outcomes measured were body weight gain, adipose tissue depot 
sizes, feed intake, body composition and mRNA abundance of several genes in different 
adipose tissues and liver.
Rats fed diets supplemented with TTA drastically reduced their body weight gain from day 10 
and onward, as compared to lard-fed controls. Similarly, feed efficiency dropped in TTA-fed 
rats and remained below lard-fed controls from day 10 and until the end of the feeding 
experiment. Feed intake fell between day 8 and 10 in rats fed TTA, but steadily increased 
thereafter, and was significantly higher than in lard-fed animals during the last two weeks of 
the feeding. Carcass analysis showed reduced amounts of fat, protein and water in rats given 
TTA, and the ratio between fat and protein content was reduced, suggesting that rats fed TTA 
became smaller as well as slimmer than the lard-fed controls. Evaluation of the different fat 
depots with magnetic resonance (MR) imaging and dissection showed that visceral tissues as 
well as abdominal subcutaneous fat depots were reduced in sizes in rats fed TTA. Relative to 
body mass, only epididymal and perirenal/retroperitoneal tissues were significantly reduced 
by TTA feeding, although mesenteric tissues tended to be similarly reduced as well. We 
measured plasma lipids, and confirmed previous results with marked reductions in TAG, 
phospholipids, cholesterol and free fatty acids, plasma glucose and insulin on the other hand 
were unchanged by TTA administration for 7 weeks. However, rats fed TTA had reduced 
plasma CRP and tended to have reduced plasma leptin and enhanced plasma adiponectin. We 
* >.!   ! (-oxidation, and observed a 3-fold increased oxidation of 
palmitoyl-CoA in livers and hearts from rats fed TTA, whereas skeletal muscle lipid oxidation 
surprisingly was unchanged when compared to lard-fed animals. Moreover, neither skeletal 
muscle glycogen content, nor insulin-stimulated glucose transport was significantly changed 
by TTA. We measured the abundance of several relevant genes in the different adipose 
tissues, but observed relatively few changes consistent in more than one adipose depot. One 
notable exception was enhanced mRNA levels of Ucp1, Fasn and Acaca in visceral adipose 
tissues, the same tissues that were most reduced relative to body weight in rats fed TTA. 
UCP1 protein levels in WATs, however, remained below the detection limits of standard 
western blotting, and may therefore not be of relevance in explaining the reduced depot mass. 
As expected, however, livers of TTA-fed rats showed marked changes in both liver size and 
gene expression, with more than 50% increase in mass and altered mRNA levels by more than 
50% of the genes examined, respectively. Among others, several genes important for uptake, 
handling, activation and oxidation of fatty acids had increased abundance in livers of TTA-fed 
rats, including Cd36, Acsl1, Cpt1, Cpt 2 and ectopic expressions of Lpl (12-fold) and Ucp3
(1900-fold). Hepatic UCP3 expression was also markedly increased in TTA-fed as compared 
to control rats.
Collectively, these data demonstrate a remarkable effect of TTA on rats fed a high-fat lard-
based diet, decreasing weight gain, while concomitantly increasing feed intake. The reduced 
feed-efficiency and plasma lipids induced by TTA-administration may partly be explained by 
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' ! (-oxidation, and possibly by increased UCP3-
mediated energy dissipation. At the same time, the enhanced levels of Ucp1 in visceral 
adipose tissues of rats fed TTA may suggest that energy uncoupling could partly account for 
the reduced feed-efficiency as well as the smaller sizes of these adipose depots relative to 
body mass. The time dependent reduction of appetite observed in TTA-fed rats, may relate to 
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seemed to reduce plasma leptin, a well-known regulator of satiety. Other mechanisms might 
explain TTA’s effect on feeding behavior, such as malonyl-CoA inhibition by TTA-CoA in 
the hypothalamus or changes in secretion of satiety-regulating peptides from the gut or brain. 
Although the latter possibilities are quite speculative, our study reveals important questions 
that remain to be answered. Hence, they illustrate the need for further studies to elucidate the 
mechanisms governing the metabolic impact of this interesting fatty acid analogue.
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7. Discussion
In paper I, we reported for the first time that chronic activation of LXRs may affect glucose 
uptake and oxidation as well as promote a strong effect by increasing fatty acid uptake and 
accumulation as complex lipids in human myotubes. Furthermore, myotubes derived from 
obese T2D subjects showed an ectopic response towards LXR-activation, with enhanced 
incorporation of PA into complex lipids and reduced PA-oxidation as compared to control 
myotubes from lean non-diabetic individuals. 
Previously, Muscat et al. have demonstrated that LXR may have functional roles in skeletal 
muscle and myotubes from mice. They could show enhanced cholesterol efflux from skeletal 
muscle treated with the LXR-activator T0901317, and observed muscle specific changes in 
mRNA abundance of several genes involved in reverse cholesterol transport and lipid 
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myotubes, suggesting a myotube-specific role of this nuclear receptor(71). Later, Dalen et al. 
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levels in human myotubes, but insulin-stimulated glucose transport was only marginally 
increased. Human myotubes traditionally display a blunt response in glucose transport 
towards insulin-stimulation as compared to skeletal muscle in vivo(240). The reason for this is 
unknown, but may involve the relatively low expression of GLUT4 with respect to GLUT1 in 
cultured myotubes (241; 242) as compared to muscle fibers in vivo(243). The nutrient 
metabolism in human myotubes also resembles more type 2 glycolytic muscle fibers, with 
enhanced basal glucose turnover, reduced insulin responsiveness and reduced fatty acid 
oxidation as compared to type 1 oxidative fibers(241; 244). Our finding of LXR-activation 
promoting fatty acid uptake and accumulation could in part be explained by the enhanced 
mRNA levels of the alleged fatty acid transporter CD36, either via direct transcriptional 
activation by LXRs or indirectly via LXR-mediated up-regulation of SREBP-!
mRNA expressions. CD36 promotes fatty acid uptake and may be translocated to the plasma 
membrane in response to insulin or contraction much like GLUT4(245; 246).
The LXR-mediated effects on lipid accumulation was later confirmed in two other studies, 
and both demonstrated an increased abundance of ACC, FAS and SCD1 in myotubes 
incubated with LXR-activators, implying enhanced de novo lipid synthesis(247; 248). In 
myotubes from subjects with T2D we further observed an ectopic response in accumulation of 
PA as compared to myotubes from lean non-diabetic subjects. Skeletal muscle from insulin 
resistant and T2D individuals in general display accumulation of more imTAG than matched 
controls, and this imTAG is thought to relate to the development of these afflictions(177; 
249). The mechanisms underlying excess imTAG storage is not clear, but seems to be related 
to obesity and thus increased availability of fatty acids(249). Storage of incoming fatty acids 
as imTAG depends on the balance between the rates of uptake and elimination. In skeletal 
muscle, fatty acids mainly arrive from the blood and are eliminated by oxidative 
catabolism(250). Activation of LXRs seemed to markedly govern fatty acid accumulation in 
human myotubes by up-regulation of the CD36 mRNA levels in both groups of myotubes 
(paper I). Bonen et al. also reported enhanced levels of membrane-bound CD36 in 
association with increased imTAG accumulation of fatty acids in obesity and T2D(251).
However, this was not observed in another study by Bruce et al.(197).
In myotubes from lean controls we observed a slight increase in fatty acid oxidation to CO2
after preincubation with the LXR-activator, whereas cells form subjects with T2D did not. 
This difference in oxidative response may partly explain the enhanced lipid accumulation, 
although the differences in magnitudes were quite substantial, with overall changes in lipid-
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accumulation being several-fold greater than in lipid oxidation. The discrepancy between 
oxidation and accumulation responses could be explained by either T2D-specific LXR-
activation/inhibition of genes involved in complex lipid synthesis or in lipolysis/re-
esterification of fatty acids. Alternatively, T2D myotubes may have an intrinsic enzymatic 
configuration favoring lipid storage that was just passively reflected by the enhanced fatty 
acid uptake caused by chronic activation of LXRs.
Skeletal muscle fatty acid uptake and oxidation must be closely regulated to avoid increased 
intracellular levels of fatty acids and other potential lipotoxic lipids. As we have discussed, 
LXRs may constitute a transcriptional switch that regulates fatty acid uptake in skeletal 
muscle and stimulates myotubes from individuals with T2D to deposit more fatty acids as 
imTAG (paper I). Fatty acid uptake and metabolism may however also be determined via 
another type of nuclear transcription factors, namely the PPARs. Fatty acids may themselves 
function as ligands for PPARs, and the specificity for any certain isoform may differ between 
them(80). Previous studies with fish oils (containing high amounts of n-3 PUFA) had shown 
beneficial effects on skeletal muscle insulin resistance in rat(129; 130). EPA has potentially 
beneficial effects on glucose uptake in skeletal myotubes, but may enhance imTAG 
accumulation(156).
In paper II we explored the impact of chronic preincubations with naturally occurring fatty 
acids and the sulfur-substituted fatty acid analogue TTA on intermediary glucose and fatty 
acid metabolism in myotubes obtained from obese T2D and obese control individuals. We 
observed that T2D myotubes have reduced capacity for palmitic acid oxidation to CO2 as 
compared to obese control cells, and that this dysfunction was improved, but not corrected by 
preincubation with TTA. Furthermore, preincubation with TTA and EPA enhanced fatty acid 
(-"!0 !.  !     ! (-oxidation intermediates with a 
significantly stronger response in T2D myotubes. Our data from human myotubes support the 
notion that skeletal muscle of insulin resistant and T2D individuals may have reduced 
mitochondrial capacity at some stage in the TCA cycle or in the electron transport chain/ATP 
synthase machinery(192; 194; 195), leading to release of ex (-oxidation intermediates 
!*.! !(-oxidation(200). Very recently, evidence have emerged indicating
that indeed reduced TCA flux in T2D myotubes may explain the reduced complete PA 
oxidation observed by us and others(252). The nuclear transcription    
important molecular regulator controlling skeletal muscle fiber type composition as well as 
fatty acid and glucose metabolism(202)6!*!> 	 - 	
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development of insulin resistance and T2D by its effects on mitochondrial biogenesis. Several 
studies have shown that skeletal muscle of T2D individuals have reduced activity and mRNA 
>  (199; 205; 206; 253). However, these data are not entirely conclusive as 
others have reported no such difference between insulin-resistant offspring of T2D parents 
and control individuals(196). We observed in paper II that fatty acid preincubation increased 
 -*!  	  *		 *-0=/?A	 *- !
 ! 
reduced response as compared to control cells. Several studies have observed that fatty acids 
	 .*	-*!n skeletal muscle, possibly via activation of 
(254; 255)6 D 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correlate positively, an effect that could help explaining the finding of increased imTAG 
storage in endurance trained individuals(256). Endurance training increases the proportion of 
 
-'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
-- >> (257) and type 1 fibers generally 
have more mitochondria, oxidize fatty acids better and show enhanced insulin-stimulated 
glucose disposal as compared to type 2 fibers(38; 39). In T2D individuals, skeletal muscle 
were associated with reduced number of type 1 fibers as well as reduced oxidative 
capacity(193-195).
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!   (-oxidation intermediates, reduced mitochondrial 
phosphorylation combined with increased fatty acid uptake, may result in high intracellular 
levels of ceramides, acyl-CoAs, DAGs and TAGs(182-185). In particular, we observed an 
enhanced response with TAG accumulation in T2D myotubes as compared to control cells 
after preincubation with either the LXR activator T0901317 (paper I) or EPA (paper II), 
both strongly promoting fatty acid uptake and accumulation. Although insulin resistance is 
associated with increased imTAG accumulation, it may not be that harmful in itself. In fact, 
recent studies have shown that genetically modified mice, either ove-expressing the TAG-
synthesizing enzyme DGAT1 (186) or knocking out the TAG-hydrolyzing enzyme 
ATGL(187), enhance imTAG storage in addition to improving glucose tolerance. Moreover, 
enhanced incorporation of incoming palmitic acid into TAG was associated with protection 
against apoptosis in cultured fibroblasts, and co-incubation with oleic acid promoted TAG 
partitioning (258) Thus, imTAG storage may rather be protective against high levels of 
insulin desensitizing lipid intermediates like acyl-CoAs, DAGs and ceramides(259).
Incubation with T0901317 also reduced PA-mediated lipotoxicity in primary human arterial 
endothelial cells, through up-regulation of SCD-1 (converting C16:0 to C16:1), improving 
incorporation of PA into more inert TAG-containing lipid droplets(260). Furthermore, lipid 
induced SCD-1 expression may similarly function to protect skeletal muscle from PA induced 
endothelial reticulum stress as demonstrated in primary human myotubes(261). In paper II
we also observed that T2D myotubes preincubated with EPA had reduced total, but enhanced 
C16:1-CoA, with increased capacity for directing incoming fatty acids either into imTAG or 
oxidation. Furthermore, neither LXR-activation nor EPA-incubation impaired insulin-
stimulated glucose uptake, and both improved glucose oxidation in myotubes from subjects 
with T2D (papers I and II).
Preincubation of control and T2D myotubes with the sulfur-substituted fatty acid TTA 
enhanced mitochondrial fatty acid and glucose oxidation, indicating increased mitochondrial 
biogenesis (paper II). TTA-feeding has been shown to increase mitochondrial content in 
skeletal muscle, liver and heart of rats(165; 262). However, in rat gastrocnemius muscle we 
!!->!(-oxidation after feeding rats TTA for 7 weeks, whereas both 
liver and heart experienced a 3-fold increase (paper IV). The explanation for this could be the 
longer feeding time (12 weeks) used in the previous studies, or alternatively the differences 
-=//    ! (-oxidation in human myotubes and rat skeletal muscle 
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human PPARs(163). This may partly explain why TTA has particularly strong effects on 
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oxidation in human myotubes(263). In paper II, however, UCP2 was the only potential 
candidate explaining the TTA-specific augmentation of mitochondrial fatty acid oxidation as 
compared to the other fatty acid preincubations. Recently, it has been speculated whether 
. 	!   ! (-oxidation may worsen rather than improve insulin 
resistance in skeletal muscle without a compensatory increase in the capacity for complete 
"!(-oxidation intermediates(200). Studies have shown improved insulin response 
= -.  !(-oxidation either chemically with CPT1 inhibitors (264; 265) or 
genetically by deletion of malonyl-CoA dehydrogenase (MCD) in mice (200) as well as in 
myotubes by MCD-specific siRNA(266). Thus, the improved mitochondrial fatty acid 
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oxidation induced by TTA in human myotubes (paper II) may not be entirely beneficial, even 
though we did observe enhanced glucose oxidation and no detrimental effects on glucose 
uptake and glycogen synthesis. Moreover, endurance trained skeletal muscles are more insulin 
sensitive despite higher capacity for fatty acid oxidation (267) and this may be related to a 
better protection against lipid peroxidation. UCP2 is thought to be involved in reducing 
oxidative stress and lipid peroxidation in mitochondria(268)0 ! 	  .* 
expression of UCPs(269). Our finding that TTA increased the UCP2 mRNA levels in human 
myotubes might therefore be a beneficial effect, protecting against mitochondrial stress 
caused by enhanced fatty !(-oxidation(200).
In paper IV, we further studied the impact of feeding rats a high-fat diet with or without 
addition of TTA on body weight gain, feed intake and adipose tissue development. Our 
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oxidation and reduced plasma lipids in rats given TTA was in accordance with previous 
publications (reviewed in(238). Furthermore, we observed that TTA-fed rats grew smaller 
while at the same time consumed more feed during the last two weeks of the study as 
compared to lard-fed controls. Carcass-data on whole animal composition indicated that TTA-
feeding restricted both adipose tissue and whole animal growth. By analyzing mRNA 
abundance we could show that TTA-feeding induced ectopic expressions of ucp3 in liver and 
ucp1 in visceral adipose tissues. Thus, increased energy dissipation by either UCP3 of UCP1 
could explain the reduced feed efficiency induced by TTA. Further analyzes by Western 
blotting revealed a concomitant increase in hepatic UCP3 protein, whereas visceral WAT 
UCP1 protein expression remained below the detection limit. The mRNA expression of ucp1 
 D/ 	  - !
!   >  (257) or activation of PPAR0 * 
controlling conversion of WAT to BAT(270). Because the initial mRNA levels of ucp1 in
visceral WATs of the control animals were very low, a 10-100-fold relative increase in TTA-
fed rats may not influence UCP1 protein levels and thus energy consumption to a sufficient 
degree in these tissues. The observed reduced visceral WAT sizes in rats fed TTA may 
therefore be explained by other factors than uncoupling, such as reduced storage or enhanced 
release of fatty acids from WAT. In a recent review, Berge et al. put forward a hypothesis 
where TTA-feeding may induce drainage of peripheral fatty acids by increase! !(-
oxidation and ketone body formation in the liver(158). Studies of rats given the 
activator fenofibrate have demonstrated de novo hepatic expression of UCP3 associated with 
enhanced energy uncoupling(271; 272), and TTA has been shown to promote mitochondrial 
energy uncoupling(273). Therefore it seems plausible that the observed reduction in feed 
efficiency may involve enhanced energy dissipation, possibly involving hepatic processes 
including UCP3 expression. Alternatively, other explanations could be reduced fat absorption 
by the gut, and hence loss of energy in the feces, or perhaps enhanced energy expenditure 
through increased locomotion and/or shivering. Our daily observations did not indicate such 
effects, and studies looking at fat in feces observed no difference between TTA and control-
fed animals, indicating that such mechanisms are less likely to explain the reduced feed 
efficiency in our study.
TTA is a pan-PPAR activator, which may explain the somewhat surprising results of reduced 
body =. . 	-!= ! ! 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activators have demonstrated both reduced weight gain as well as feed intake(84; 274),
whereas addition of rosiglitazon increases feed consumption (107) and weight gain(109).
Hence, rats fed dual and pan-PPAR agonists may experience a combination of opposing 
PPAR effects, as observed with ragaglitazar (109) or TTA (paper IV). We cannot, however, 
exclude the possibility of other mechanisms promoting the increased feed intake caused by 
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TTA administration, such as reduced leptin concentration in plasma or more direct 
interactions between TTA and the hypothalamic regulation of feeding behavior.
Paper I and II revealed the need for more convenient, recourse and time-saving methods for 
assaying fuel handling, such as nutrient uptake, accumulation and oxidation to CO2. The 
relevance of better screening techniques was also exemplified in a paper by Ukropcova et 
al(189). They used an improved method for assaying fatty acid oxidation (275) to show 
important correlations between intrinsic oxidative capacities in human myotubes and 
metabolic donor-characteristics, like respiratory quotient and insulin sensitivity. This 
prompted us to develop two new methods for measurement of nutrient handling in cells 
grown in 96-well plates (paper III). Our new methods are versatile, less laborious and more 
cost-effective than previous assays, and they have successfully been implemented in recent 
publications(248; 263; 276), including paper II. We think that application of these new 
assays will enable researchers to improve their understanding of nutrient metabolism under 
different cellular conditions in a cost-effective way.
Cultured human myotubes as a model of skeletal muscle
Cultured human myotubes are morphologically, metabolically and biochemically similar to 
adult skeletal muscle(277), and thus is a valuable ex vivo model to distinguish between 
genetic and environmental factors in the etiology of e.g. insulin resistance(278). Satellite cells 
are isolated from skeletal muscle biopsies and then proliferated and differentiated to become 
mature myotubes. Primary satellite cells form human or animal donors may proliferate for 
many passages as well as frozen and thawed like immortalized cell-lines. The drawbacks are 
that isolation of pure satellite cell colonies may not be complete, thus importing minor 
impurities with different cell types such as fibroblasts. There is also some discussion about 
whether the satellite population may have more than one linage, and the composition of this 
mix is not exactly known, or perhaps not even fixed from one human to another. Furthermore, 
culturing of primary human myotubes generally takes more time than other cell-lines because 
of slower growth. Another drawback related to T2D research is that measurements of insulin-
stimulated glucose uptake tend to be only about 50% increased as compared to basal uptake, 
thus making it more difficult to investigate differences in this parameter. Several genes in 
	 *-*!.8B/+0!/("
!=>>ls than in 
skeletal muscle in vivo.
Cultured human myotubes are the most similar cell system to intact skeletal muscle that can 
be modulated ex vivo. Compared to rodent models they express the right genetic background 
as well as some of the specific skeletal muscle phenotype. The extracellular environment can 
be controlled precisely and kept relatively constant over time, without interference by 
systemic homeostatic compensatory mechanisms. We and others have reported several 
potential intrinsic deficiencies in myotubes from individuals with T2D including lower basal 
palmitate oxidation(237), and impaired insulin-stimulated glucose metabolism(240; 278). In a 
recent paper Ukropcova et al. demonstrated that the ability to suppress fatty acid oxidation 
with glucose in human myotubes in vitro was negatively associated with the in vivo metabolic 
flexibility (MF) and insulin sensitivity (IS) of the donors as measured by euglycemic 
hyperinsulinemic clamp(189). Furthermore, in the same study, the degree of fatty acid 
oxidative adaption by the myotubes towards increasing concentrations of fatty acid in the 
medium was positively correlated with individual donor IS and MF(189).
Choosing a proper control is important for what conclusions may be drawn on the etiology of 
the diabetic phenotype. As we and others have mainly worked with myotubes derived from 
obese individuals with T2D, perhaps the most proper control would be to use myotubes form 
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individuals without T2D, but with similar BMI. However, if obesity is such a strong 
determinant for the development of T2D, obese subjects without signs of T2D might be 
considered a “super-cohort” that may be especially adapted at tackling the metabolic stresses 
associated with overnutrition. On the other side, choosing slim subjects without T2D, could 
mean that they belong to the same cohort as the obese T2D subjects, only that they have not 
by any reason become obese and consequently have not developed T2D. 
In this thesis paper I utilized lean control myotubes whereas paper II used “obese” ones. 
There seemed to be a more clear difference in fatty acid complete oxidation to CO2 between 
myotubes in paper II than in paper I, and that may be because skeletal muscle of obese non-
diabetic subjects are better suited than average to handle fatty acids without detrimental 
effects on insulin signaling. This aspect, however, needs to be further clarified in future 
studies.
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8. Conclusion
In this thesis we demonstrate that:
1. Skeletal muscle of insulin resistant and T2D individuals may have reduced 
mitochondrial oxidative capacity. Thus, when T2D myotubes experience increased 
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    (-oxidation 
intermediates, perhaps to avoid cellular damage or disruption of cellular functions. 
2. Fatty acids or LXR-agonists may enhance fatty acid uptake in skeletal myotubes, and 
after preincubation with either T0901317 or EPA imTAG storage was particularly 
enhanced in T2D relative to control myotubes. 
3. Increased storage of fatty acids as imTAG may function as a protective mechanism 
against high levels of insulin-desensitizing lipid intermediates such as acyl-CoAs and 
DAG. EPA specifically decreased acyl-CoA levels in T2D myotubes, and 
preincubations with both EPA and T0901317 improved, rather than worsened glucose 
handling in control as well as T2D myotubes. 
4. TTA improved mitochondrial glucose and fatty acid oxidation in diabetic as well as
control myotubes, without detrimental effects on insulin-stimulated glucose uptake 
and glycogen synthesis. Furthermore, TTA reduced body weight gain but increased 
feed intake in rats fed a high-fat diet, indicating effects of this hypolipidemic fatty acid 
analogue on whole body energy consumption.
5. Previous laborious methods for measuring cellular nutrient uptake and CO2-catabolism 
can be scaled down to 96 wells format, allowing the use of SPAs and our novel CO2-
trapping technique, thereby providing more time and cost-effective analyzes.
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